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Gliomas are primary brain tumors in adults and are categorized by the World Health 
Organization (WHO) as grade I and II (low-grade gliomas), grade III (anaplastic) and 
IV (glioblastoma)1. Glioblastoma encompass 15% of all brain and central nervous 
system tumors and almost half of all primary brain tumors2. Astrocytoma and glio-
blastoma are categorized by the mutational status of the gene encoding for isocitrate 
dehydrogenase (IDH): IDH-mutant (IDHmt) and IDH wild-type (IDHwt). By definition, 
oligodendroglioma is both 1p19q codeleted and IDHmt1. While the exact diagnosis 
and tumor grade is determined by assessment of molecular markers and histology, 
Magnetic Resonance Imaging (MRI) can give information on the diagnosis as well. 
General features that can help predict glioma grade are presence or lack of contrast-
enhancement and necrosis. More advanced measures such as Apparent Diffusion 
Coefficient (ADC) derived from Diffusion Weighted Imaging (DWI)3.4 and regional 
cerebral blood volume (rCBV) from perfusion imaging can also have added value and 
are therefore often included in clinical glioma scanning protocols5,6.
mri methods
MRI images are constructed by inducing alignment of hydrogen nuclei (protons) 
using a strong magnetic field (usually 1.5 or 3.0 tesla), after which the alignment 
is disturbed with a radiofrequency (RF) pulse. When the RF-pulse has ended, the 
protons realign themselves and emit signals while doing so. The exact location of 
every signal can be determined with the help of magnetic gradients and frequency 
encoding, which make sure that every voxel emits a slightly different signal. The 
signals are then processed to form an image.
The realignment signals are two-fold: there is the T1 signal (recovery of longitu-
dinal relaxation) and the T2 signal (decay of transverse magnetization). The main 
MRI sequences are therefore T1-weighted and T2-weighted images. Differences in T1 
and T2 relaxation times between different tissues allow distinction between tissues. 
Images can be reconstructed as well using more advanced techniques. For instance, 
when the water signal is nulled in a T2-weighted sequence, we are left with a T2-
weighted FLuid Attenuation Inversion Recovery (FLAIR) image, which is a very useful 
image when looking at white matter abnormalities.
If a gadolinium-based contrast-agent is administered and a T1-weighted image 
is acquired, blood vessels and areas with a defective blood-brain-barrier (as is the 
case many tumors) enhance. Contrast-enhanced scanning can also be used for the 
evaluation of brain perfusion. There are several different methods to measure brain 
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perfusion, and the method used in this thesis is Dynamic Suscepti bility Contrast (DSC) 
MR perfusion, from which relati ve cerebral blood volume (rCBV) can be esti mated. 
Examples of gliomas on structural imaging and perfusion imaging can be seen in 
fi gure 1 and fi gure 2.
Diff usion-weighted imaging (DWI) and diff usion tensor imaging (DTI) are MRI meth-
ods in which the degree of diff usion of water molecules within a voxel is measured. 
Certain ti ssues are more dense than others, aff ecti ng diff usion. Isotropic diff usion 
means that a water molecule can move freely in any directi on, while anisotropic 
diff usion indicates one or more barriers preventi ng free diff usion. The anisotropy 
can also be used to determine the general directi on of diff usion within a voxel and 
aft er linking voxels together, the general directi on of white matt er fi bers can be 
determined7.
Response assessment and follow-up of pati ents with brain tumors can include 
structural MRI (T1-weighted, T2-weighted and FLAIR images), advanced MRI (dif-
fusion, perfusion and spectroscopy) and nuclear medicine imaging (Single-Photon 
Emission Computed Tomography or SPECT and Positron Emission Tomography or 
PET), and is described in more detail in chapter 3.1.
Figure 1. (A) Example of a low-grade glioma on a T2-weighted image. (B) Contrast enhancement of 
glioblastoma on a post-contrast T1-weighted image.
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Pre-treatment assessment in Gliomas
Before surgery, Diff usion Tensor Imaging (DTI) scans can be made for localizati on 
of important fi ber tracts. Further post-processing of DTI-scans provides a variety of 
parameter maps, such as Mean Diff usivity (MD), Fracti onal Anisotropy (FA), pure 
isotropy (p) and anisotropy (q). The p and q maps have been used by Price et al.8,9 to 
determine the extent of infi ltrati ve growth of glioblastoma along white matt er tracts 
in associati on with IDH-mutati on status. In chapter 2, Price’s method is replicated 
and applied to non-enhancing gliomas (i.e. presumed low-grade) to see if it allows 
predicti on of IDH-mutati on status and 1p19q codeleti on status in this specifi c pati ent 
group.
Post-treatment assessment in Gliomas
While chapter 2 focuses on pre-treatment characteristi cs in non-enhancing gliomas, 
chapter 3 focuses on response assessment aft er treatment. Treatment of glioma 
includes surgery, radiotherapy and chemotherapy at fi rst diagnosis10. At recurrence, 
other and someti mes experimental treatment opti ons are considered, including 
nitrosoureas, retreatment with temozolomide, and angiogenesis inhibitors. Tumors 
need a steady supply of nutrients and oxygen to grow. Normal blood vessels in the 
area of the tumor are insuffi  cient to fulfi ll the demands of the tumor and so the 
tumor induces growth of new blood vessels: angiogenesis. Angiogenesis can be 
blocked by targeti ng endothelial cells directly or by inhibiti ng specifi c signal-mole-
Figure 2. (A) Example of a recurrent glioblastoma with enhancement on the T1-weighted post-
contrast image, (B) surrounding non-enhancing abnormaliti es on the FLAIR-image and (C) a DSC-




cules released by the tumor. An important signal-molecule, produced in abundance 
by glioblastoma, is Vascular Endothelial Growth Factor (VEGF)11. The most commonly 
used angiogenesis inhibitor in glioblastoma is the VEGF- inhibitor bevacizumab (or 
Avasti n®), which has been granted full approval by the United States Food and Drug 
Administrati on (FDA) in 2017 for second-line treatment in recurrent glioblastoma12. 
Bevacizumab is oft en given in combinati on with a chemotherapeuti c agent.
Whether a recurrent glioblastoma is responding to treatment is based on MRI 
and clinical features. The Response Assessment in Neuro-Oncology (RANO) criteria 
include 2D measurements of enhancing tumor and an esti mati on of change in non-
enhancing abnormaliti es. Additi onally, the appearance of new lesions, steroid use 
and clinical status are taken into account13 (see Figure 3). There are two main prob-
lems when it comes to response assessment: 1) pseudo-response, and 2) pseudo-
progression. Pseudo-progression is an increase in enhancement on the T1-weighted 
post-contrast scan caused by prior radiotherapy. It mimics actual tumor growth, 
while in fact is refl ects radionecrosis. In chapter 3.1, imaging of pseudo-progression 
is described in detail.
Pseudo-response is seen aft er treatment with angiogenesis inhibitors and 
describes the decrease in enhancement of the tumor and also a decrease in non-
enhancing abnormaliti es without an actual decrease in tumor size. As the eff ect of 
pseudo-response is seen early aft er start of treatment, early radiological treatment 
response assessment can be a challenge. Early assessment is important because it 
provides valuable informati on on whether the tumor is responding to treatment or 
not. If a treatment is ineff ecti ve, there is no reason to conti nue, especially in the light 
of potenti al serious side eff ects. A diff erent treatment might be considered in some 
pati ents. Additi onally, radiological measures can provide informati on on the pati ent’s 
prognosis. Measuring this early treatment response with the 2D RANO criteria in 
Figure 3. Example of 2D RANO measures in enhancing glioblastoma at baseline (A) and follow-up 
(B). There is progressive disease (PD) because the enhancing lesion has grown in size and a new 
enhancing lesion has appeared next to it.
13
General Introduction
those with pseudo-response is suboptimal at best and therefore we evaluated a va-
riety of different methods for determining treatment response in this patient group.
It has been argued that volumetric measures are an improvement over 2D mea-
sures, especially in glioblastoma, because these heterogeneous tumors with asym-
metrical growth could be measured more reliably with a volumetric approach, and 
also because semi-automated volumetric tumor segmentation was shown to have 
lower intra- and interrater variability than manual measures14,15. In chapter 3.2, the 
2D RANO criteria were compared with volumetric measures in recurrent glioblastoma 
treated with classical chemotherapy and/or bevacizumab. Change in tumor volume 
was measured between baseline (before treatment) and first/second follow-up. In 
chapter 3.3, the quantitative approach to this volumetric response assessment is 
explored.
Measures other than tumor size might provide more information on treatment 
response (or lack thereof) in those treated with bevacizumab. Previous studies 
have shown that low values of Apparent Diffusion Coefficient (ADC) derived from 
DWI at baseline and after treatment (i.e. diffusion restriction) may be predictive for 
survival16,17. Studies that look at perfusion imaging derived, relative Cerebral Blood 
Volume (rCBV) find that an increase in rCBV from pre- to post-treatment decreases 
survival, while a decrease improves survival18. Early changes in diffusion after therapy 
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Background. Extent of mismatch between tumor delineations drawn on Diffusion 
Tensor Imaging (DTI) derived isotropic (p) and anisotropic (q) maps have been shown 
to distinguish isocitrate dehydrogenase (IDH) wild-type (wt) and mutated (mt) 
glioblastomas. We use this technique in non-enhancing gliomas to determine if an 
assessment of IDH-mutation as well as 1p19q codeletion status can be made.
Methods. All patients undergoing presurgical DTI for non-enhancing glioma 
between 2004 and 2013 from a single center were included (n=83). A targeted 
Next-Generation Sequencing panel (NGS) was used to determine the presence of 
IDHmt and 1p19q codeletion. A volume of interest (VOI) was drawn on the p-map 
and subsequently overlaid on the q-map to determine overlap with white matter 
tracts (>0.5cm) by 2 observers. Extent and pattern of mismatch was scored as: I) 
no indication of infiltration (i.e. no p/q mismatch), II) single focus of infiltration, III) 
multifocal infiltration, IV) expansion of lesion into white matter tracts, and V) infiltra-
tion following white matter tracts. Different patterns found in IDHmt versus IDHwt 
and 1p19q codeleted versus non-codeleted tumors were compared with a Mann-
Whitney U test. Cohen’s Kappa was calculated to assess interobserver agreement.
Results. Four of the non-enhancing gliomas were IDHwt, 29 were both IDHmt and 
1p19q codeleted, and 50 IDHmt without 1p19q codeletion. The 4 IDHwt gliomas all 
had a different pattern of infiltrative growth (i.e. patterns II, III, IV, and V). These 
same patterns were also seen in the IDHmt glioma group. No significant differ-
ences between codeleted and non-codeleted tumors were found (Mann-Whitney 
U=714.0, p=.908). The interobserver agreement was moderate with a Kappa of 0.473 
(SE=0.068) or 62.7%.
Conclusion. Because of overlap in growth patterns between IDHwt versus IDHmt 
and 1p19q codeleted versus non-codeleted gliomas and the suboptimal interob-
server concordance, this DTI-derived technique does not allow for the distinction of 
possible different molecular subtypes in non-enhancing gliomas.
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Advances in knowledge
• Patterns of mismatch between DTI-derived isotropic and anisotropic maps do not 
predict IDH-mutation or 1p19q codeletion status in non-enhancing gliomas.
• While successfully applied in glioblastoma, this technique has moderate inter-
rater agreement when used for assessment of non-enhancing glioma growth 
patterns.
Implications for patient care
• Possible differences in growth pattern between non-enhancing glioma molecular 
subtypes could not be distinguished using p/q mapping and so we currently do 
not recommend using this technique for non-enhancing gliomas in a clinical set-
ting.
Summary statement
Previous research indicates that different molecular subtypes of glioblastoma (i.e. 
IDH-mutated versus IDH wild-type) can be discerned based on the extent/pattern 
of mismatch assessed on isotropic and anisotropic diffusion maps. Using this same 
technique in non-enhancing glioma, we found no differences in growth pattern be-





The 2016 update of the WHO classification for central nervous system tumors pres-
ents a major change in the classification of gliomas: not only histological, but also 
molecular features now characterize different types of gliomas. The WHO 2016 clas-
sification distinguishes between two types of astrocytoma based on the mutational 
status of the gene encoding for isocitrate dehydrogenase (IDH) 1 or 2: IDH-mutant 
(IDHmt) and IDH wild-type (IDHwt) astrocytoma. Oligodendroglioma are character-
ized by the presence of a codeletion of chromosomal arms 1p and 19q and an IDH1/2 
mutation1. The incidence of IDH mutation in grade II and III gliomas (according to the 
WHO 2007 classification) is 60-80%, leaving a subset of lower-grade glioma to be 
IDHwt2. Many of these IDHwt tumors with grade II or III histological features present 
without enhancement on imaging. The prognosis of these patients is poor compared 
to that of patients with IDHmt gliomas especially in the presence of a TERT promotor 
mutation3.
IDHmt gliomas with a 1p19q codeletion (oligodendrogliomas) have a better 
prognosis than those without a codeletion (astrocytoma, IDHmt). A non-invasive 
identification of the different molecular subtypes of non-enhancing gliomas can help 
discern a subgroup of more aggressive tumors from the more indolent ones. Not only 
will this lead to a more accurate prediction of molecular subtypes, but it may also aid 
in guiding treatment decisions.
The presence of enhancement is generally considered a sign of aggressiveness, 
however in its absence, other characteristics, such as growth patterns could be in-
formative. Differences in glioma growth between subtypes of non-enhancing tumors 
(oligodendroglioma and IDHmt or IDHwt astrocytoma) have not been extensively 
explored. Infiltrative growth has been reported in both astrocytoma and oligoden-
droglioma, although in oligodendrogliomas areas with more compact infiltration 
can also be present4. Glioma infiltration occurs along perineuronal structures (also 
known as perineuronal satellitosis), subpial, and perivascular structures, as well as 
along white matter fibers. In extreme cases, the tumor infiltrates throughout the 
brain resulting in a gliomatosis cerebri pattern seen on imaging5.
While displacement or destruction of white matter tracts is fairly easy to determine, 
infiltration of a tract is more difficult to assess6. With Diffusion Tensor Imaging (DTI) 
the microstructural properties of different tissues can be determined by measuring 
diffusion of water molecules. When water molecules are restricted in their diffu-
sion, such as in the presence of white matter tracts, this is reflected in DTI-derived 
parameters of anisotropy (q) and isotropy (p)7. The use of q eliminates the possible 
confounding effect of changes in the overall diffusion, as is the case when measur-
ing the fractional anisotropy (FA). Combining anisotropic measures with isotropic 
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measures, such as Mean Diffusivity (MD), Apparent Diffusion Coefficient (ADC), and 
pure isotropy (p) can help determine tumor infiltration along white matter tracts. 
In enhancing/high-grade tumor it has been shown that in biopsy-proven areas of 
infiltration, p is abnormally high, while q is within a normal range8-10. The mismatch 
between p and q has been used by Price et al. to determine the extent of infiltrative 
growth along white matter tracts in IDHmt and IDHwt glioblastoma11,12. In IDHmt 
(and 8% of IDHwt) glioblastoma, a minimally invasive pattern was found, while in ID-
Hwt glioblastoma, a locally invasive or diffusely invasive pattern was encountered10. 
These findings led us to apply this technique in the group of patients with presumed 
low-grade gliomas (i.e. non-enhancing tumors without necrosis).
We hypothesize that assessing the ‘mismatch’ between p and q could help visu-
alize different growth patterns in non-enhancing gliomas and as such differentiate 




Adult patients with suspected low-grade glioma (i.e. without enhancement and 
necrosis) that had undergone presurgical functional MRI (fMRI) and DTI between De-
cember 2004 and June 2014 in the Erasmus MC in Rotterdam (NL) were considered 
for retrospective analysis. Approximately 125 patients with suspected low-grade 
glioma were operated in this timeframe, 90 of whom had undergone presurgical DTI 
in preparation of awake-surgery. Targeted Next-Generation Sequencing panel (NGS) 
was performed on the archival tumor tissue to determine presence of IDH1- and 
IDH2-mutations and 1p19q codeletion and other molecular lesions characteristic of 
glioblastoma13. The institutional review board approved of the design of the study. 
Previously, Wijnenga et al.3 reported on 65 of the 90 patients included in our study 
focusing on pre- and postoperative tumor volumes in relation to molecular informa-
tion; DTI-data was not included in this prior analysis.
Tumors were categorized according to the presence or absence of an IDH-mutation 
(IDHmt respectively IDHwt) and 1p19q codeletion according to the WHO 2016 clas-
sification1. Patients with partial imbalance or loss of only one chromosomal arm were 
categorized as non-codeleted. Overall Survival (OS) was defined in years from the 
date of the preoperative DTI-scan until death.
Chapter 2
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Data acquisition and processing
All scanning was performed at 1.5 or 3.0 tesla field strength (GE Healthcare, Milwau-
kee, IL, USA) with a matrix of 256x256 and an in-plane resolution of less than 1mm2. 
All data were acquired with a minimum of 25 directions (all with b=1000 s/mm2) and 
1-4 b=0 s/mm2 images. For more details see Supplementary Files table S1.
DICOM files were converted to NIfTI format for processing in FSL (Oxford, UK)14. 
Images were reoriented and corrected for eddy currents using the b=0 s/mm2 image 
as a reference. The brain was extracted using BET (Brain Extraction Tool)15 with a 
threshold of 0.3. FSL-DTIFit was used to extract the eigenvectors, eigenvalues and 
mean diffusivity, which were then used to create a pure isotropic map (p) and an 
anisotropic map (q) with a custom script using FSLmaths according to equations from 
Price et al.16:
with b=1000 s/mm2) and 1-4 b=0 s/mm2 
images. For more details see Supplementary 
Files tableS1. 
DICOM files were converted to NIfTI format 
for processing i  FSL (Oxford, UK)14. Images 
were reoriented and corrected for eddy 
currents using the b=0 s/mm2 image as a 
reference. The brain was extracted using BET 
(Brain Extraction Tool)15 with a threshold of 
0.3. FSL-DTIFi  was used to extract the 
igenv ctors, eigenvalues and mean 
diffusivity, hich were then used to cre te a
pure isotropic map (p) and an anisotropic map 
(q) with a custom script using FSLmaths 
ccording to equations from Price et al.16: 
= √3D 
𝑝𝑝 =  √3𝐷𝐷 
𝑞𝑞 = √(𝜆𝜆1 − 𝐷𝐷)2 + (𝜆𝜆2 − 𝐷𝐷)2 + (𝜆𝜆3 − 𝐷𝐷)2 
Where D is the mean diffusivity and λ the eigenvalues:
 
Where D is the mean diffusivity and λ the 
eigenvalues: 
 
𝐷𝐷 = (𝜆𝜆1 + 𝜆𝜆2 +  𝜆𝜆3)/3 
 
Data analysis 
A volume of interest (VOI) of the tumor area 
was drawn manually by one observer on the 
p-map using MRIcron (Chris Rorden, 
www.mricro.com, version 6.6.2013). Clearly 
recognizable blood vessels were excluded.  
We overlaid the VOI from the p-map on the q-
map to visually determine overlap with white 
matter tracts (i.e. high-intensity areas on the 
q-map). A VOI exceeding >0.5cm in three 
directions over such high intensity areas was 
considered to be a p/q-mismatch, indicating 
infiltration of the white matter tract8 
(Figure1). The p/q mismatch was categorized 
by two independent observers (i.e. an 
experienced neuro-radiologist and a radiology 
resident) as follows: I) no indication of 
Data analysis
A volume of interest (VOI) of the tumor area was drawn manually by one observer on 
the p-map using MRIcron (Chris Rorden, www.mricro.com, version 6.6.2013). Clearly 
recognizable blood vessels were excluded.
We overlaid the VOI from the p-map on the q-map to visually determine overlap 
with white matter tracts (i.e. high-intensity areas on the q-map). A VOI exceeding 
>0.5cm in three directions over such high intensity areas was considered to be a 
p/q-mismatch, indicating infiltration of the white matter tract8 (Figure 1). The p/q 
mismatch was categorized by two independent observers (i.e. an experienced neuro-
radiologist and a radiology resident) as follows: I) no indication of infiltration (i.e. no 
p/q mismatch), II) single focus of infiltration, III) multifocal infiltration, IV) expansion 
of lesion into white matter tracts, and V) infiltration following white matter tracts 
(Figure 2). A combination of options was allowed. Both observers were blinded for 
histological and molecular tumor status. Interobserver agreement was determined 
by calculating Cohen’s Kappa Coefficient. In case of discrepancy, the maps were 
reviewed again by the two obs rvers together to assign the category in consensus, 
which was then used for furth r analyses. The difference in incidence within each 
p/q mismatch category between molecular tumor categories was c mpared using a 
Mann-Whitney U test.
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Figure 1. Example of a non-enhancing tumor with a peripheral localizati on, clearly visible on the 
p-map (A). Tumor segmentati on was performed on the p-map (B) and subsequently overlaid on the 
q-map (C, D). An additi onal line drawn on image D shows the locati on of mismatch. This example 
was classifi ed as ‘expansion of lesion into white matt er tracts’.
Chapter 2
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Figure 2. Examples of diff erent p/q mismatch patt erns: ‘single focus of infi ltrati on’ (A), ‘multi focal 
infi ltrati on’ (B), and ‘infi ltrati on following white matt er tracts’ (C). Additi onal lines have been drawn 
to show the locati on of mismatch.
results
Patients
In 7 pati ents NGS could not be performed since there was no tumor ti ssue avail-
able. The fi nal analysis was performed on the remaining 83 pati ents (49 men and 34 
women). Mean and median age was 39 years (range, 20 to 72 years). At the ti me of 
analysis, 29 pati ents had died with a median OS of 4.2 years (range, 0.9 to 9.2 years). 
Four (13.8%) of these pati ents had a 1p19q codeleted tumor.
Tumors were located in the frontal lobe in 41 (49.4%), the insula in 17 (20.5%), tempo-
ral lobe in 9 (10.8%), and parietal lobe in 4 (4.8%) pati ents. The remaining tumors were 
located in both the frontal and parietal lobes in 5 (6.0%), the parietal and temporal lobes 
in 5 (6.0%), and in more than 2 lobes in 2 (2.4%) pati ents. There was a left  hemispheric 
predominance, with 69.9% (n=58) of tumors located in the left  hemisphere.
Molecular data
In 79 of 83 pati ents, an IDH1 or IDH2 mutati on was found with the main subtype 
IDH-R132H found in 66 pati ents. Other subtypes found were R132C (n=4), R132G 
(n=3), IDH1-R132S (n=2), IDH2-R172K (n=3), and IDH2-R172M (n=1). Four pati ents 
with an IDHwt tumor were deceased at the ti me of analysis with a median OS of 2.0 
years (range, 2.5 to 4.2 years). In the IDHmt tumor group, 25 (31.6%) pati ents had 
died with a median OS of 4.4 years (range, 0.9 to 9.2 years). Additi onal molecular 
informati on in the 4 IDHwt pati ents revealed TERT mutati ons (all 4), imbalance or 
loss of chromosome 7 and 10 (including PTEN; 3 pati ents), and EGFR amplifi cati on (2 
pati ents), all corresponding with glioblastoma13.
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In the 79 IDHmt tumors, 29 (34.9%) were 1p19q codeleted, while 50 tumors were 
non-codeleted. The 2 tumors growing in more than 2 lobes were both IDHmt without 
a 1p19q codeletion.
p/q assessment
A discrepancy between the initial ratings by the 2 observers was present in 31 (37.3%) 
cases. In the discrepant cases, consensus was reached by agreeing with observer 1 
in 11 cases and with observer 2 in 14 cases. In the remaining 6 cases a new category 
was assigned. All final ratings are shown in Table 1. The interobserver agreement was 
moderate with Kappa=0.473 (SE=0.068).
Table 1. Incidence of p/q mismatch categories (final assessment by 2 observers in consensus) in 












I No indication of infiltration 2 (2.5%) - 2 (4%)
II Single focus of infiltration 4 (5.1%) 1 (25%) 1 (3.4%) 3 (6%)
III Multifocal infiltration 23 (29.1%) 1 (25%) 10 (34.5%) 13 (26%)
IV Expansion of lesion into WM tracts 25 (31.6%) 1 (25%) 9 (31%) 16 (32%)
V Infiltration following WM tracts 20 (25.3%) 1 (25%) 7 (24.1%) 13 (26%)
III and IV 3 (3.8%) - - 3 (6%)
IV and V 2 (2.5%) - 2 (6.9%) -
The predominant p/q mismatch categories in the IDHmt group were III) multifocal 
infiltration (29.1%), IV) expansion of lesion into white matter tracts (31.6%), and V) 
infiltration following white matter tracts (25.3%). The 4 patients with IDHwt tumor 
each showed a different category of p/q mismatch, i.e. II) single focus of infiltration, 
III) multifocal infiltration, IV) expansion of lesion into white matter tracts, and V) 
infiltration following white matter tracts, rendering these 4 IDHwt tumors indistin-
guishable from the IDHmt tumors.
In the 1p19q codeleted group (n=29) and non-codeleted group (n=50), the main 
p/q mismatch categories were III (34.5% respectively 26.0%), IV (31.0% respectively 
32.0%), and V (24.1% respectively 26.0%). No significant difference in the incidence 





Our study showed that the major groups of molecularly defined glioma subtypes 
(oligodendroglioma and IDHmt or IDHwt astrocytoma) in non-enhancing gliomas 
cannot be discerned based on infiltrative growth pattern assessed on DTI-derived 
isotropic and anisotropic maps. The 4 IDHwt tumors each showed a different pattern 
of tumor growth, while no differences in the various growth patterns between 1p19q 
codeleted and non-codeleted tumors were observed.
Glioma growth can lead to destruction, infiltration, edema or displacement of 
white matter tracts6,17. Destruction and tract displacement are easily recognized. A 
displaced tract can still be intact despite being compressed (sometimes increasing 
anisotropic values)18. Infiltration and edema of white matter tracts are more difficult 
to assess, as in both we see an increase in isotropic and a variable decrease in aniso-
tropic values. In infiltrated white matter tracts the anisotropy is dependent on the 
amount of tumor infiltration and the degree to which the tracts are intact18. Different 
models looking at glioma growth find that anisotropic parameters are more suited to 
assess tumor infiltration than isotropic parameters19-22.
Anisotropic values (q or FA), however, need to be looked at in context with isotro-
pic values (p or MD or ADC). In the gross tumor, p or MD is increased and q or FA is 
reduced compared to normal tissue. But regions surrounding the tumor (high T2w 
signal) can consist of edema and/or infiltrating tumor, leading to abnormally high p 
or MD values, while q or FA values may be within normal range8,9,23. This mismatch 
between p and q has successfully been used to describe different infiltrative patterns 
in IDHmt and IDHwt glioblastoma by Price et al. They describe three different pat-
terns of infiltration: a minimally invasive pattern, which is seen in all IDHmt and in 
8% of IDHwt glioblastomas, a locally invasive pattern, and a diffusely invasive pattern 
seen in 23% and 69% of IDHwt glioblastomas respectively10-12. We used a slightly 
adapted categorization of these mismatch patterns to better capture the different 
growth patterns we encountered in non-enhancing gliomas. Categories I and II (‘no 
indication of infiltration’ and ‘single focus of infiltration’) are similar to Price et al.’s 
‘minimally invasive’ pattern. In patients with more extensive white matter tract 
infiltration, however, we found both tumors that clearly followed white matter tracts 
and tumors that expanded into a large section of the tract. This distinction was felt 
not to be captured by simply categorizing both growth patterns as ‘diffusely invasive’, 
and thus further specified in our categorization.
Based on Price et al.’s findings in glioblastoma, we expected the non-enhancing 
IDHwt tumors (even if only present in 4 patients) to predominantly expand into or 
to infiltrate along white matter tracts and IDHmt tumors to express a less invasive 
growth pattern. Instead, we found that each of the 4 IDHwt tumors had a different 
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pattern of growth, ranging from minimally invasive (single focus of infiltration) to 
infiltration along white matter tracts. These same patterns were found in the IDHmt 
group. We were therefore unable to identify the IDHwt tumors based on their growth 
patterns as assessed with p/q mapping. Similarly, we were unable to distinguish 
1p19q codeleted from non-codeleted tumors with this technique. Possible explana-
tions for the lack of ‘positive’ findings are first that growth patterns between these 
molecular subtypes are in fact not significantly different, and second that potentially 
existing differences cannot be distinguished with p/q mapping.
Very little is known about growth patterns of non-enhancing glioma molecularly 
defined subtypes. Both codeleted (oligodendroglioma) and non-codeleted (astro-
cytoma) gliomas are known to infiltrate along white matter tracts, but this seems 
to be more common in astrocytoma24,25. It should be noted that these previous 
studies included both enhancing and non-enhancing tumors. While based on these 
studies on 1p19q codeletion and the study by Price et al. on IDH-mutation status 
in glioblastoma10 differences in growth pattern between molecularly defined glioma 
subtypes are conceivable, it is possible that these findings can not be translated to 
the non-enhancing, lower grade (II/III) tumors and that in these tumors no significant 
differences in growth pattern are in fact present.
Alternatively, our ‘negative’ results may be related to the p/q mapping technique. 
We found that determining growth patterns in small and peripherally located tumors 
was problematic: in the peripheral, smaller tracts, the threshold for p/q mismatch of 
0.5cm10 was difficult to apply, because the lower anisotropy in the peripheral tracts 
hindered assessment of further reduction in anisotropy due to tumor infiltration. 
This likely contributed to the low agreement between the observers (62.7%). Price 
et al. reported an interobserver agreement of 90% (26), a difference that can be 
explained the study population (glioblastoma versus non-enhancing glioma) as well 
as the different number of categories (3 versus 5 categories).
The retrospective nature of this study introduced a selection bias towards patients 
who were eligible for awake-surgery, because preoperative DTI is only performed for 
these surgeries at our institution. These patients are generally in a better condition 
and of a younger age than those not selected for awake surgery and more often have 
a tumor located in the left hemisphere (for preservation of language function). This 
selection bias may also have resulted in the low number of only 4 IDHwt gliomas, 
since patients with IDHwt tumors tend to be older and thus less eligible for awake 
surgery. We furthermore only included non-enhancing gliomas, in which IDHwt 
is likely to be less frequent than in enhancing tumors. Despite this low number, it 
was clear that each of the IDHwt gliomas showed a different growth pattern that 
overlapped with patterns seen in IDHmt tumors. Our conclusion that p/q mapping 
in these patients does not distinguish between IDHwt and IDHmt thus remains valid.
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In conclusion, we were unable to translate previous findings from glioblastoma, 
showing that p/q mapping can be used to discern different molecular subtypes, 
to non-enhancing glioma. Based on our findings, we do not recommend using this 
technique to determine molecular status in non-enhancing glioma.
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44 14200** 70-85 1-3/25 2.0 256x256 0.859
DISCOVERY MR450
(1.5 tesla)





13 8000 68-73 1-3/25 3.5 256x256 0.820
Signa HDxt
(3 tesla)
4 16000 86 4/31 2.0 256x256 0.820
DISCOVERY MR750
(3 tesla)
1 7925 88 4/32 2.5 256x256 0.938
* 5 patients were scanned with 5mm slice thickness.
** 4 deviations from protocol with TRs of 16000, 15525, 15450 and 15500
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Response evaluation and follow-up 
by imaging in brain tumours
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Brain tumours, either primary or secondary, are frequent. Primary brain tumours 
include mainly glioma, lymphoma and meningioma. Secondary tumours, i.e. brain 
metastasis, are a frequent event during the disease course of patients with cancer. 
The evaluation of response to treatment is often difficult with structural imaging 
due to the interference of treatment effects. In this chapter, the role of advanced 
imaging for the differential diagnosis between pseudoprogression, radiation necro-
sis and tumour recurrence is described with perfusion and diffusion MR imaging, 
MR spectroscopy, and PET imaging with amino acid analogues, fluorodeoxiglucose 
and other tracers. Furthermore, the commonly used response criteria for various 
brain tumours are described. For glioma, these are those set out by the Response 
Assessment in Neuro-Oncology (RANO) group. For brain metastases the RANO-brain 
metastasis (RANO-BM) and RECIST criteria are commonly used. While conventional 
T1w post-contrast imaging is the mainstay imaging modality for basic response as-
sessment, multimodal imaging is commonly necessary to evaluate the response to 
treatment of primary and secondary brain tumours.
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introduction
Brain tumours can be either primary (gliomas, lymphomas, meningiomas) or second-
ary (metastases). They carry a substantial burden of severe symptoms and complica-
tions. Their treatment often includes radiotherapy. The evaluation of tumour response 
can be challenging particularly in gliomas with the issue of pseudoprogression. For 
all tumours, another challenge is to differentiate radiation necrosis from tumoural 




Treatment response assessment of brain tumours is generally performed using 
structural magnetic resonance (MR) images, such as T2-weighted (T2w), T2w Fluid 
Attenuation Inversion Recovery (FLAIR), and pre- and post-contrast T1-weighted 
(T1w) imaging. Most tumours show enhancement on post-contrast T1w images and 
2D measurements on this sequence remain the basis of treatment assessment.
Additional information on tumour pathophysiology can be obtained with advanced 
MR imaging techniques and nuclear medicine imaging.
Advanced MR imaging
Diffusion weighted imaging (DWI) and diffusion tensor imaging (DTI) can be consid-
ered as both structural and functional techniques. The amount of diffusion (or ran-
dom motion) of water molecules is measured with DWI. In DTI, diffusion is measured 
in multiple directions (minimum of 6) to calculate the tensor or general direction of 
diffusion. Diffusion can be limited due to structures within the voxel. In tumour, high 
cellular density restricts diffusion, which is reflected in the DWI-derived Apparent 
Diffusion Coefficient (ADC)1. DTI-derived measures include fractional anisotropy (FA), 
which provides information on the degree of directional diffusion along the three 
main axes, and mean diffusivity (MD), which is similar to ADC2. It is important to 
note that ADC is not only influenced by extracellular space tortuosity, but also by 
membrane damage and perfusion3.
Most commonly used for perfusion imaging is T2*-weighted dynamic suscepti-
bility-weighted contrast-enhanced (DSC) imaging. When the blood-brain-barrier is 
breached, contrast-agent leaks from the vessels into the surrounding tissue, increasing 
T1w-signal intensity and decreasing the T2*-signal. This effect must be counteracted 
(either in advance or during post-processing) when maps of relative cerebral blood 
volume (rCBV) are calculated, but can also be used to calculate other parameters, 
such as the peak height (PH) and percentage signal intensity recovery (rPSR)4. Other 
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perfusion techniques include dynamic contrast enhanced (DCE) imaging and arterial 
spin labelling (ASL). DCE-derived measures include cerebral blood flow (CBF), capil-
lary permeability (Ktrans), and extravascular extracellular volume fraction (Ve)5. Where 
for both DSC- and DCE-imaging intravascular injection of contrast-agent is required, 
the blood itself forms the contrast in arterial spin labelling (ASL). ASL-derived CBF has 
been shown to correlate well with DSC-derived rCBV measures6.
In MR spectroscopy different resonance frequencies of specific molecules and 
metabolites can be measured within different tissues, most commonly using protons 
(1H-MRS). In brain tumours, N-acetyl aspartate (NAA), Choline (Cho), myo-Inositol 
(mI), lactate/lipid Lac), and Creatine (Cr) are commonly assessed, although many 
more may be measured7.
Chemical Exchange Saturation Transfer (CEST) imaging is a more recent technique, 
which can be used to measure amides (-NH), amines (-NH2), and hydroxyl (-OH) 
groups among others, but is still very much in the research arena8.
Nuclear medicine imaging
Nuclear medicine techniques such as single photon tomography (SPECT) and positron 
emission tomography (PET) are being used worldwide for the characterisation, therapy 
planning and recurrence assessment of brain tumours. SPECT using cellular viability 
radiotracers like as 99mTechnetium- sestamibi (99mTc-MIBI) and 201Thallium were 
initially employed in clinical practice due to its high availability9,10. However, in recent 
years PET has been gradually introduced into the clinical practice instead of SPECT 
for the evaluation of brain tumours as a complementary and supplementary tool of 
standard MR imaging sequences. It is important to note that fusion images between 
structural (computed tomography (CT) and/or MR imaging) and PET or SPECT images 
are highly recommended to achieve better accuracy. Multimodality systems are now 
available that combine SPECT and PET scanners and structural imaging devices like 
CT (SPECT-CT and PET-CT) and more recently MR imaging (PET-MR imaging). Visual 
analysis of images is the most common method for scan evaluation in clinical practice. 
The study is classified as positive when the activity observed in the lesion exceeds 
the reference region (usually normal cortex). However, semiquantitative analysis of 
PET studies can also be performed using the standard uptake value (SUV), commonly 
calculated for quantifying systemic tumours. This parameter however has a limited 
role in the clinical interpretation of images in neuro-oncology. Instead, tumour or 
lesion to brain reference region ratios using mean or maximum SUV (TBR) are used 
to provide a measure of PET radiotracers uptake in brain tumours.
One of the hallmarks of PET is the variety of parameters that can be observed 
and measured in brain tumours by means of specific radiotracers. Some of the most 
commonly used in clinical practice are reviewed in this section.
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Glucose metabolism
Brain 2-deoxy-2-[18F]-2-fluoro-2-deoxy-D-glucose (FDG) uptake is usually acquired 
45 to 60 minutes after the injection of 185 MBq of FDG. Patients must be fasting 
for 4 hours prior to injection, and it is recommended to obtain a measurement of 
blood glucose prior to the exam: high blood glucose levels at the time of injection 
decreases uptake in tumour and healthy tissue, although it may not affect lesion 
detection detectability. In case sedation is required, this can be carried out 45-60 
minutes after injection, just prior to the time of the acquisition11.
FDG accumulates in the majority of tumours due to elevated glucose metabolism 
in response to increased energy demand. This technique has been applied to brain 
tumour imaging for many years. The relationship of FDG uptake to tumour glioma 
grade and prognosis has been reported in several studies12. However, FDG is in some 
way limited in neuro-oncology due to the high rate of glucose metabolism in normal 
brain parenchyma resulting in diminished signal-to-noise ratio for brain tumours. 
Another problem with FDG is the high uptake of this tracer in inflammatory cells, 
which can occur in a variety of disease processes and can be independent of tumour 
growth or response13. Consequently, as newer PET tracers have become available, 
the use of FDG for imaging in neuro-oncology has declined.
Amino acid transport
System L amino acid transport PET radiotracers ([11C-methyl]-methionine (-MET), 
O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) and 3,4-dihydroxy-6-[18F]-fluoro-L-phenyl-
alanine (FDOPA) are currently used in neuro-oncology. MET has been used since 
198314, but is limited to centres with an on site cyclotron because it is labelled with 
11Carbon, a radioisotope with a very short half-life (20 minutes). FET and FDOPA are 
labelled with 18Fluorine, a radioisotope with a longer half-life, which allows radio-
tracer transportation from the manufacturing laboratory to the PET centre12.
The uptake of radiolabelled amino acids observed in normal brain tissue as well 
as in brain lesions including tumours of many types is predominantly conditioned by 
the transmembrane active transport, which is responsible for the biological activity 
in tissues, including cell proliferation. The uptake by cerebral tumour tissue appears 
to be caused almost entirely by increased transport via the specific amino acid 
transport system L for large neutral amino acids12. The uptake is also influenced by 
passive diffusion in regions with blood-brain-barrier disruption, and by stagnation in 
regional vascular beds that depends on blood volume due to a large vascular bed15. 
In contrast to tumour, the uptake of radiolabelled amino acids in normal brain is very 
low resulting in a high contrast between tumour and normal brain tissue.
After a recommended period of 4 hours of fasting, 200 MBq of FET, 370-555 MBq 
of MET, or 185 MBq of FDOPA are injected and a static PET acquisition is performed 
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20 minutes later. In addition to static images, dynamic FET PET data can be acquired, 
which allows the characterisation of the temporal pattern of FET uptake by deriving 
a time-activity curve (TAC) in brain tumours16,17. It remains to be shown, however, 
whether dynamic MET and FDOPA can contribute significantly to the characterisation 
of brain tumours. The more widespread use of amino acid PET for the management 
of patients with brain tumours has been strongly recommended by the Response 
Assessment in Neuro-oncology (RANO) group13,18.
Somatostatine receptors
The most common somatostatin receptor (SSTR) radioligands for PET imaging are 
68Ga-DOTA-Tyr3-octreotide (68Ga-DOTATOC), 68Ga-DOTA-D-Phe1-Tyr3-octreotate 
(68Ga-DOTATATE) or 68Ga-DOTA-l-Nal3-octreotide (68Ga-DOTANOC). These ra-
diotracers, frequently used for imaging of neuroendocrine tumours, have been 
introduced in neuro-oncology due the overexpression of SSTR subtype 2 in almost all 
meningiomas19. 68Ga has a physical half-life of 68 minutes and can be produced with 
a 68Ge/68Ga generator system, which enables in-house production without the need 
for an on-site cyclotron. PET ligands to SSTR provide high sensitivity with excellent 
target-to-background contrast due to low uptake in bone and healthy brain tissue20.
There are no comparative studies of 68Ga-DOTATOC, 68Ga-DOTATATE and 68Ga-
DOTANOC, but the uptake of all these tracers is relatively high compared to normal 
brain; thus, possible differences between these tracers are not really relevant. Pro-
cedure guidelines for PET imaging with 68Ga-DOTA-conjugated peptides have been 
published recently21.
Other radiotracers
Several other radiotracers are used to image brain tumours. The thymidine nucleoside 
analogue 3’-deoxy-3’-18F-fluorothymidine (FLT) is a substrate for thymidine kinase-1 
and reflects cell proliferation. Although previous studies suggest that FLT is a promis-
ing tool for glioma detection and grading22 and is able to predict improved survival 
after bevacizumab therapy22,23, the uptake of this tracer is dependent on disruption 
of the blood-brain barrier, thereby limiting its clinical value.
Hypoxia in brain tumours has been demonstrated with use of the PET tracer 
18F-Fluoromisonidazole (FMISO)24. FMISO enters tumour cells by passive diffusion 
and becomes trapped in cells with reduced tissue oxygen partial pressure by nitrore-
ductase enzymes. This tracer thus allows the identification of hypoxic tumour areas, 
which are thought to be more resistant to irradiation25, as well as a trigger for neo-
angiogenesis. Thus far, FMISO has predominantly been used in a preclinical setting.
Another interesting PET target is the translocator protein (TSPO), a mitochondrial 
membrane protein that has been used as biomarker for neuroinflammation. TSPO is 
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highly expressed in activated microglia, macrophages and neoplastic cells. Imaging 
with the TSPO ligand 11C-(R)PK11195 demonstrates increased binding in high-grade 
glioma compared to low-grade glioma and normal brain parenchyma26. More re-
cently, the TSPO ligand 18F-DPA-714 labelled with 18F has been evaluated in glioma 
animal models27.
Choline is a marker of phospholipid synthesis involved in the synthesis of cell 
membrane components. The radiolabelled choline (either 11Carbon and more 
recently 18Fluorine) is trapped by glioblastoma with a very high contrast to normal 
brain, whereas its role in lower grade gliomas is limited28. When compared with FDG, 





Newly diagnosed anaplastic glioma and glioblastoma (GBM) are the most frequent 
primary brain tumours in adults. They are treated with the Stupp protocol, consisting 
of surgery, whole-brain radiotherapy (WBRT) and temozolomide (TMZ), followed by 
adjuvant TMZ. In diffuse low-grade gliomas the presence of certain negative prog-
nostic factors can be considered a reason for adjuvant radiotherapy30. The effects 
of radiotherapy combined with TMZ positively influences patient survival in GBM, 
especially in those with a methylated O6-methylguanine DNA methyltransferase 
(MGMT)31,32.
Radiological treatment assessment
Radiological assessment of treatment response in glioma was traditionally based on 
the bidimensional measurement of the area of enhancement33, but the introduction 
of angiogenesis inhibitors (such as bevacizumab) has led to the diagnostic challenge 
of pseudoresponse: enhancement decreases or disappears because the tumour 
vasculature normalises and is therefore no longer permeable, while the tumour itself 
may not be responding to treatment. The RANO criteria34 therefore now includes 
the assessment of non-enhancing in addition to enhancing lesions, which also 
make them applicable to non-enhancing, commonly lower grade, glioma. The time 
between scans is generally 6-12 weeks, but is sometimes increased in case of stable 
disease. A summary of the RANO criteria for both GBM and lower grade glioma can 
be found in Table 1.
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Table 1. Summary of the RANO criteria for glioblastoma (GBM) and low-grade glioma (LGG)34,37.
Response Criteria GBM Criteria LGG
CR Requires all of the following: complete 
disappearance of all enhancing (non-) 
measurable disease sustained for at least 
4 weeks. No progression of non-enhancing 
disease. No new lesions. No corticosteroids. 
Stable or improved clinically.
Requires all of the following: complete 
disappearance of the lesion on T2w/
FLAIR images. No new lesions aside from 
radiation effects. No corticosteroids. Stable 
or improved clinically.
 PR Requires all of the following: ≥50% decrease in 
the sum of products of perpendicular diameters 
of all measurable enhancing lesions compared 
to baseline sustained for at least 4 weeks. No 
progression of non-enhancing disease. No new 
lesions. Stable or reduced corticosteroids. Stable 
or improved clinically.
Requires all of the following: ≥50% 
decrease in the sum of products of 
perpendicular diameters on Tw/FLAIR 
imaging compared to baseline sustained 
for at least 4 weeks. No new lesions aside 
from radiation effects. Stable or reduced 




- Requires all of the following: 25-50% 
decrease of non-enhancing lesion area on 
T2w/FLAIR images compared to baseline. 
No new lesions aside from radiation 
effects. Stable or reduced corticosteroids. 
Stable or improved clinically.
 SD Does not qualify for CR, PR or PD. Stable or 
reduced corticosteroids. Stable clinically.
Does not qualify for CR, PR, minor 
response or PD. No new lesions aside 
from radiation effects. Stable or reduced 
corticosteroids. Stable or improved 
clinically.
PD Requires any of the following: ≥25% increase in 
the sum of products of perpendicular diameters 
of enhancing lesions compared to the smallest 
tumour measurement from earlier studies. 
Significant increase in non-enhancing lesions. 
Any new lesion. Clinical deterioration.
Requires any of the following: 
Development of new lesions or increase 
of enhancement. ≥25% increase of T2w/
FLAIR non-enhancing lesions while on 
stable or increasing steroid-dosage and 
not caused by radiotherapy or other. 
Clinical deterioration.
*CR=complete response, PR=partial response, SD=stable disease, PD=progressive disease.
Advanced methods of treatment assessment (MR imaging)
In a pretreatment setting, diffusion MR imaging derived parameters, such as ADC and 
FA, can aid in grading gliomas and localising areas of high cellularity suitable for bi-
opsy35. After treatment, however, these parameters no longer correlate with cellular 
density, as they are influenced by other factors such as cell swelling and necrosis36. At 
a group level, ADC values still tend to be higher in gliomas than in normal appearing 
white matter (NAWM), but at an individual level there is considerable overlap and 
they are therefore not useful for response assessment37.
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Perfusion imaging derived rCBV and CBF in both grey and white matter are de-
creased after radiotherapy and can remain low for up to 6 and 9 months respectively 
in high-dose areas38,39. High rCBV values (>2.0 times that of the contralateral NAWM) 
can be used to distinguish tumour from pseudo-progression or radiation necrosis 
with reported sensitivities of up to 82% and specificity of 78%40,41. In diffuse astrocy-
toma, an increase in rCBV indicates malignant transformation37. In oligodendroglioma 
rCBV tends to be moderately increased even when low grade, but a further increase 
indicates malignant transformation37.
MR spectroscopy shows (transient) changes in molecules and metabolites in rela-
tion to treatment-related changes, such as neuronal dysfunction, oedema, damage 
to oligodendrocytes, demyelination, and inflammatory effects. Metabolites such as 
NAA, Cr, Cho and Lac change during and after radiation. For instance, a decrease in 
NAA occurs early after radiotherapy co-occurring with an increase in Cho, which can 
remain present for up to 6 months42-44. Due to the transient nature of metabolite 
changes, MR spectroscopy results need to be either interpreted in combination with 
other measures (MR imaging and/or PET) or with repeated measures in time.
PET imaging
A higher FDG uptake by glioma is correlated with higher tumour grade and worse 
prognosis45-47. With the exception of pilocytic astrocytomas, WHO grade I and II 
grade gliomas are typically negative on FDG PET (uptake similar to or less than white 
matter), and consequently this tracer is not suitable for response evaluation of low-
grade glioma13. On the other hand, increased levels of FDG uptake in enhancing brain 
lesions are correlated with tumour recurrence in anaplastic glioma and glioblastoma.
In recurrent high-grade glioma, the uptake of FDG has been shown to be predic-
tive of tumour metabolic response to TMZ versus TMZ plus radiotherapy48, and for 
predicting survival following anti-angiogenic therapy with bevacizumab45.
Current amino acid PET data suggest that both a reduction of amino acid uptake 
and/or a decrease of the metabolically active tumour volume are signs of treatment 
response associated with improved long-term outcome13. Moreover, the amount of 
residual tracer uptake in FET PET after surgery/prior to chemoradiation of glioblas-
toma (within 7-20 days after surgery) has a strong prognostic influence, even after 
adjustment by multivariate survival analyses for the effects of treatment, MGMT 
promoter methylation and other patient and tumour-related factors (Figure 1)49. The 
experience with amino acid PET for monitoring after treatment in patients with WHO 
grade II glioma is however limited.
The prognostic value of early changes of FET uptake 6-8 weeks after postoperative 
radiochemotherapy in glioblastoma patients has been evaluated prospectively50,51. 
PET responders with a decrease in the TBR of more than 10% had a significantly 
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longer disease-free and overall survival than pati ents with stable or increasing tracer 
uptake aft er radiochemotherapy. The kineti c analysis of FET uptake was not helpful 
in the evaluati on of treatment eff ects to radiochemotherapy50. Pati ents with low-
grade glioma evaluated 12 months aft er brachytherapy exhibit signifi cantly reduced 
MET uptake52,53. For pati ents treated with alkylati ng chemotherapy, MET and FET 
PET may improve response assessment54. Reliable monitoring of temozolomide and 
nitrosourea-based chemotherapy (PCV scheme including procarbazine, CCNU and 
vincristi ne or CCNU monotherapy) has been demonstrated in pati ents with recur-
rent high-grade glioma55. Similarly, FET PET has been used to assess eff ects of TMZ 
according to the EORTC protocol 22033-26033 (applicati on of 75 mg/m2 TMZ per day 
over 21 days in a 28-day cycle)56. Additi onally, a reducti on of the metabolically acti ve 
tumour volume aft er treatment initi ati on can be observed considerably earlier than 
volume reducti ons on FLAIR imaging57. Several studies suggest that treatment re-
sponse and outcome in bevacizumab therapy can be assessed bett er with amino acid 
PET using 18F-FET and 18F-FDOPA than with MR imaging (see also secti on 4.2)58,59.
Lymphoma
Background
The classifi cati on of central nervous system (CNS) lymphoma now corresponds with 
the WHO 2016 classifi cati ons of systemic haematopoieti c/lymphoid disease60. A 
Figure 1. Neuroimaging studies of a pati ent with anaplasti c astrocytoma performed 1 month aft er 
postoperati ve radiochemotherapy. An area of contrast enhancement on the T1w MR imaging se-
quence (A) is observed in the medial aspect of the residual surgical cavity. The MET-PET study (B) and 
MR imaging - PET fusion (C) show an absence of MET uptake in this part of the lesion ruling out the 
presence of tumour and indicati ng an area of pseudoprogression However, there is also an area of 
elevated MET uptake (TBR: 2.56) in the most lateral part of the lesion surrounding the area of pseu-
doprogression, suggesti ng the presence of infi ltrati ve tumour relapse and as confi rmed by biopsy.
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disti ncti on is made between primary CNS lymphoma (PCNSL) and secondary CNS 
lymphoma. Secondary CNS lymphoma generally arises from aggressive non-Hodgkin 
lymphoma and has commonly (2/3) a leptomeningeal, and less commonly (1/3) a 
parenchymal localisati on. PCNSL almost invariably has a parenchymal localisati on. 
Typically, single or multi ple contrast-enhancing lesions are seen surrounding the 
ventricles or in the corpus callosum61. Pati ents are treated with WBRT and multi ple 
chemotherapeuti c agents (including methotrexate) given both systemically and 
intrathecally or intraventricularly. Additi onally steroids are given.
Radiological treatment assessment
Conventi onal treatment response assessment of brain parenchymal lymphoma is by 
contrast-enhanced MR imaging with an average ti me between follow-up scans of 
2 months during therapy. The Internati onal Primary CNS Lymphoma Collaborati ve 
Group has determined response criteria in 2005. Complete response (CR) is deter-
mined by a lack of contrast-enhancement on MR imaging, no steroid-treatment and 
Figure 2. FLAIR and T1w post-contrast images in a 60-year old man with PCNSL in the right frontal 
lobe (A and B), treated with rituximab and MBVP followed by WBRT (30 Gy in 20 fracti ons) with 
resulti ng parti al remission. Treatment conti nued with cytarabine and WBRT with SIB (30Gy in 20 
fracti ons) and an additi onal boost on the tumour (10Gy in 20 fracti ons), resulti ng in complete remis-
sion with minimal white matt er abnormaliti es considered to be a post-treatment eff ect (C and D). 
Recurrent disease four years later (E and F). Aft er renewed treatment with MBVP and WBRT (20Gy 
in 5 fracti ons), a clear response was seen. Periventricular white-matt er abnormaliti es and ex vacuo 
dilati ons of the ventricles is present as a post-treatment eff ect (G and H).
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normal eye examinati on and cerebrospinal fl uid (CSF) cytology. An unconfi rmed 
complete response (CRu) is CR with minimal abnormaliti es on MR imaging and eye 
examinati on and/or any steroid use. Pati ents with a parti al response (PR) have a 
50% decrease of enhancing tumour without or only minor or decreasing eye dis-
ease with either negati ve or persistent/suspicious CSF cytology. Progressive disease 
(PD) is characterised by a ≥25% increase in enhancing lesions, new sites of disease, 
recurrent or new ocular disease and recurrent or positi ve CSF cytology62. Treatment 
response in parenchymal PCNSL is depicted in Figure 2.
PET imaging
PCNSL oft en have high cellular density and consequently a markedly increased FDG 
uptake compared to other brain tumours, including glioblastoma and metastasis, and 
when compared to many infecti ous and infl ammatory processes13,63. Cerebral infec-
ti ons such as toxoplasmosis and tuberculoma are a common diff erenti al diagnosis to 
PCNSL and exhibit a signifi cantly lower uptake than pati ents with lymphoma, with no 
overlap of the uptake values (0.3-0.7 versus 1.7-3.1 respecti vely)64,65.
There is no signifi cant diff erence between MET PET and FDG PET in terms of sen-
siti vity66. FDG PET has shown some clinical advantage in the diff erenti al diagnosis of 
lymphoma as most cerebral lymphomas have a high cell density and a high glucose 
metabolism, which is usually even higher than that of malignant gliomas and cerebral 
metastasis. In additi on, FDG it is clinically more available and it can be performed as 
a whole-body scan for the assessment of systemic lymphoma involvement. Inter-
esti ngly, FDG PET might also useful to demonstrate a response to chemotherapy in 
lymphoma pati ents very early aft er the initi ati on of therapy (Figure 3)67.
Figure 3. Brain FDG PET of primary CNS lymphoma at baseline (A), and 3 months aft er two cycles of 
chemotherapy (Carmusti ne, Methotrexate, Cytarabine, Rituximab according to the R-BAM scheme) 
and autologous hematopoieti c stem cell transplantati on (B) showing complete response.
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Metastasis
Background
The main primary sites of brain metastases are lung, breast, and skin (melanoma). 
About 80% of brain metastases are located in the supratentorial brain (mainly frontal 
lobes) and about half of all patients have more than one metastases at the time 
of diagnosis68. Treatment consists of WBRT and/or stereotactic radiosurgery (SRS) 
depending on the size and number of lesions. Larger metastases may be surgically 
removed69.
Radiological treatment assessment
The RANO Brain Metastases (RANO-BM) working group created radiological criteria 
for treatment assessment in clinical trials, which can also be used in clinical practice70. 
The metastases are categorised as target and non-target lesions. Target lesions are 
parenchymal metastases of at least 10x5 mm2 in size. Up to five target lesions can be 
Table 2. Response assessment in brain metastases: target and non-target lesions according to the 








CR Requires all of the following:
• Disappearance of all target lesions sustained for at least 4 weeks.
• No new lesions.
• No corticosteroids.
• Stable or improved clinically.
PR Requires all of the following
• ≥30% decrease in the sum of perpendicular diameters of target lesion size compared 
to the baseline sustained for at least 4 weeks.
• No new lesions.
• Stable or reduced corticosteroids.
• Stable or improved clinically
SD Does not qualify for CR, PR of PD.
PD Requires all of the following:
• ≥20% increase in the sum of longest diameters of target lesions compared to the 
smallest sum from earlier studies.










CR Requires all of the following:
• Disappearance of all enhancing non-target lesions
• No new lesions.
PR/SD Persistence of one or more non-target lesions.
PD Requires any of the following:
• Unequivocal progression of existing enhancing non-target lesions.
• New lesions (except while on immunotherapy-based treatment*)
• Unequivocal progression of existing tumour-related non-enhancing (T2w/FLAIR) 
lesions.
*In case of immunotherapy-based treatment, new lesions alone may not constitute PD.
**CR=complete response, PR=partial response, SD=stable disease, PD=progressive disease.
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measured. Non-target lesions include smaller parenchymal lesions, but also dural, 
leptomeningeal, and cystic (or non-measurable) lesions. In case of a mixed response 
to treatment, lesions that increase in size are considered leading. Recommended 
time between scans is 6-12 weeks. Aside from radiological features, the RANO-BM 
also includes clinical status and steroid dosage. The RANO-BM criteria can be found 
in Table 2. Other response assessment methods include the RECIST criteria, in which 
lesions are measured in a single direction (≥30% decrease in the sum of diameters 
of the target lesions constitutes partial response, and a ≥20% increase progressive 
disease) and the WHO criteria, which include bi-dimensional measures (≥50% de-
crease in in the sum of the product of the diameters constitutes partial response, and 
≥25% increase progressive disease). The appearance of a new lesion always indicates 
progressive disease71.
PET imaging
PET imaging in the context of treatment assessment of metastasis is mostly used to 
distinguish tumour recurrence from treatment effects (see section3).
FDG PET can add to the specificity for enhancing lesions that are equivocal or 
suspicious for recurrent tumour based on contrast-enhanced MR imaging alone in 
patients with brain metastases treated with SRS72.
Meningioma
Background
The WHO classification distinguishes three grades of meningiomas: Grade I, or 
benign meningioma, constitute the vast majority (about 90%); Grade II (atypical) 
and grade III (malignant) meningiomas are considerably less common. Benign me-
ningiomas can be eligible for (radio)surgery if the cause of symptoms. Radiotherapy 
can be considered in case of incomplete resection or at recurrence. Atypical and 
malignant meningiomas are surgically removed when possible and irradiated60,73,74. 
Both atypical and malignant meningiomas can metastasise to the lungs, liver and 
spine, although this is rare (0.1% of cases) and screening is therefore not routinely 
recommended75.
Radiological treatment assessment
Meningiomas at risk for recurrence are those with pial invasion, and in the case of grade 
II and III meningioma when there is bone involvement or peritumoural oedema76,77. 
Meningiomas generally show intense homogeneous enhancement on post-contrast 
T1w images, and measurements are therefore performed on this sequence. Gener-
ally, the modified MacDonald criteria are used to determine treatment response, but 
it has been suggested that volumetric measures are more sensitive when it comes to 
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Figure 4. CT, MR imaging (T1w post-contrast), angiographic and FDG-PET images in a 40-year old 
woman with grade II meningioma primarily located in the skull (A and B). The tumour was resected 
and irradiated with 59.4Gy. Recurrent tumour growth appeared fi ve years later intracranially (C) 
with compression of the superior sagitt al sinus (D). Again, the tumour was resected. At second re-
currence, multi ple intracranial meningiomas appeared within the radiati on fi eld (E) and the pati ent 
was irradiated again (49.5Gy in 33 fracti ons). Aside from intracranial disease, the pati ent had histo-
logically confi rmed metastases in the lungs (F).
Chapter 3.1
46
determining tumour growth due to the slow-growing nature of the tumours78. Ad-
ditional meningiomas may appear in the course of time at other locations.
Early radiotherapy-related effects are tumour necrosis and oedema in the white 
matter79. Radiation-induced peritumoural changes occur in about 25% of patients, 
mainly in convexity, parasagittal and falx cerebri meningiomas after SRS80. Later 
radiotherapy-effects such as white matter abnormalities are often seen in high-dose 
areas and the periventricular white matter. An example of an irradiated patient with 
an atypical meningioma and its treatment course of depicted in Figure 4.
PET imaging
The use of PET in meningioma patients is gradually increasing. Nevertheless, the 
usefulness of FDG PET is limited because meningiomas are mostly slow-growing and 
the metabolism of FDG is only elevated in atypical or anaplastic meningiomas81.
MET PET scanning has been used to evaluate the effect of stereotactic high-energy 
proton beam treatment has been evaluated in a prospective study with 19 menin-
gioma patients82. A reduction in the TBR was observed (even over several years) in 
the total patient group without a reduction in tumour size. Moreover, prior to the 
volume increase on MR imaging, MET uptake ratios were found to be increased, 
suggesting that treatment effects can be seen earlier than with CT or MR imaging82.
Even though amino acid PET exhibits a better tumour-to-background contrast 
than FDG PET, the availability of specific SSTR ligands with even higher tumour-to-
background contrast has led to a limited use of amino acid PET in meningioma assess-
ment54. 68Ga-DOTA peptides PET have been shown more accurate than standard MR 
imaging to discriminate meningioma tissue from scar tissue related to pretreatment 
using both DOTATOC83 and DOTATATE20, even in transosseous extension of intracranial 
meningiomas84. Consequently, 68Ga-DOTA peptides may be useful in cases of unclear 
differential diagnosis between tumour progression and treatment-induced changes.
treatment effects
Pseudo-progression and radiation necrosis
Background
Progressive disease can be mimicked by treatment-related toxicity from radiother-
apy (pseudoprogression and radiation necrosis), immunotherapy, chemotherapy, 
and anti-epileptic drugs. Additional imaging techniques and sequential imaging 
combined with clinical characteristics may be needed to distinguish these entities 
from actual progressive disease70,74. Pseudoprogression occurs in a subacute set-
ting after radiotherapy treatment combined with TMZ (within approximately 2-3 
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months after the start of treatment). Tumours with a methylated O6-methylguanine 
DNA methyltransferase (MGMT) promotor respond best to TMZ. Initially it seemed 
that this group showed a higher incidence of pseudoprogression, but this has later 
been disputed85. Direct damage after radiotherapy is likely due to vasodilatation and 
increased capillary permeability, leading to disruption of the blood-brain-barrier and 
oedema. In case of pseudoprogression the response is excessive causing enhance-
ment on post-contrast T1w images due to the damage to the blood-brain-barrier, and 
which is indistinguishable tumour progression86.87.
Radiation necrosis is a chronic response to radiotherapy, which can occur from 
just months up to many years (median 1-2 years) after treatment; up to 90% oc-
curs within the first 5 years posttreatment. There is endothelial damage, enzyme 
changes and immunological response leading tot necrosis. Radiation necrosis similar 
to pseudoprogression causes enhancement on post-contrast T1w images, mimicking 
tumour recurrence or progression86,88.
The reported incidences of pseudoprogression and radiation necrosis vary widely, 
from 2% to 48%, depending on the source and the definition used. The incidence is in-
fluenced by radiation dose, field size, number of fractions, prior WBRT, chemotherapy 
(mainly cisplatin, carboplatin, doxorubicin, methotrexate, and temozolomide), im-
munotherapy, length of survival, age at time of radiotherapy, and diabetes mellitus88.
Standard structural imaging
Distinguishing pseudoprogression and radiation necrosis from tumour residue or recur-
rence is challenging. Radiation-induced lesions can occur at the primary tumour site, 
but also at a distance, including the contralateral hemisphere, if included in the field 
of radiation. There is a predilection for white matter, especially the corpus callosum, 
because of the higher susceptibility of oligodendrocytes to radiation damage (compared 
to neurons) and relatively lower blood supply89. In patients with low-grade gliomas there 
is also a predilection for subependymal localisation90. The enhancing area is surrounded 
by oedema, which tends to be somewhat more extensive in radiation-induced lesions91. 
Different patterns of enhancement have been described, including nodular and rim 
enhancement with either regular or irregular margins and combined nodular and linear 
enhancing foci that create a mosaic-like appearance88,92, but no reliable distinctive 
characteristics have been found. Radiation-induced lesions more often contain haemor-
rhagic lesions visible on T2*-weighted images, although these can also occur in glioma 
and metastases (especially malignant melanoma)88. To complicate things further, lesions 
containing both radiation damage and tumour commonly occur. Patients with multiple 
lesions can show a mixed response, which can indicate the presence of pseudoprogres-
sion or radiation necrosis. More advanced imaging techniques, follow-up and sometimes 




With diff usion MR imaging, ADC values tend to be lower in recurrent tumour com-
pared to radiati on necrosis at the group level, likely due to increased cellularity, 
but at the individual level these values overlap93. Comparing ADC measures from 
the enhancing and non-enhancing areas can be helpful: in case of tumour, the ADC 
values taken from the non-enhancing area tend to be signifi cantly higher than those 
from the enhancing area, while in radiati on necrosis ADC values from both enhancing 
and non-enhancing areas are similar88. DTI-derived FA values in enhancing areas tend 
to be higher in recurrent tumour than in radiati on necrosis94.
Figure 5. T1w post-contrast, FLAIR and DSC-perfusion rCBV maps in a glioblastoma pati ent with new 
enhancing lesions (A) and surrounding oedema (B) aft er prior treatment by the Stupp protocol. The 
rCBV map (C) shows low perfusion in the enhancing areas. The pati ent was enrolled in a clinical trial 
and treated with both bevacizumab and lomusti ne. At 6 weeks’ follow-up the enhancement had 
disappeared (D) and the surrounding oedema was decreased (E). A small artefact is present on the 
rCBV map (F), but there is no evidence of increase in perfusion.
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Perfusion-imaging derived rCBV is commonly assessed as a ratio of the area of interest 
over the normal appearing white matter (NAWM) in the contralateral hemisphere. 
In high-grade tumours and metastases the rCBV ratio is high, whereas in radiation 
necrosis/pseudoprogression the rCBV ratio is low. The proposed cut-off value lies 
between 1.5 and 2.640,41. In about 8% of cases results are false-negative, as tumours 
can have rCBV ratios <1.5. Radiation necrosis can be safely diagnosed when the ratio 
is <0.6 (Figure 5)41,95. In current clinically used software it is easy to measure rCBV in 
multiple regions of interest (ROIs), but the interrater variability is quite large when 
it comes to deciding ROI size and placement. Other methods for measuring perfu-
sion, such as using a different contrast-agent than gadolinium like ferumoxytol and 
using a different technique such as ASL are under investigation, showing promising 
results96.97.
MR spectroscopy shows different metabolite concentrations in radiation necrosis 
from those measured in tumour. Reductions in individual metabolites Cho, Cr, and 
NAA indicate tissue damage and thus radiation necrosis. Favouring tumour are high 
ratios of Cho/Cr and Cho/NAA and low ratios of NAA/Cr and Lac/Cho. In order to dis-
tinguish tumour from radiation necrosis different cut-off values for these ratios have 
been proposed: Cho/Cr >1.5-1.8, Cho/NAA >1-1.8, and Lac/Cho <0.75-1.0543,98,99. 
Single voxel MR spectroscopy techniques requires precise placement of the voxel 
to be measured. In the presence of mixed tumour and radiation necrosis within the 
same voxel, tumour signal can be obscured because the metabolite concentration is 
averaged and then tends to suggest inflammatory changes43. Such partial volume ef-
fects can be reduced with multivoxel MRS, in which multiple small voxels are placed. 
It is sometimes also important to look at changes over time, because of certain 
transient changes in metabolite concentrations: Cho for instance can be temporality 
increased in radiation necrosis, falsely indicating tumour presence99.
A relatively new method of measuring metabolites is CEST, which can potentially 
also be used to distinguish radiation damage from tumour: Amide proton transfer 
(APT), for instance, is found to be increased in tumour tissue8. CEST studies to date 
are still scarce and the true clinical value remains to be determined.
PET imaging
After radiation therapy, FDG can be used to distinguish radiation necrosis from recur-
rent glioma. Although different rates of diagnostic accuracy has been have been re-
ported in the literature, FDG seems to be less sensitive than amino acid radiotracers 
with lower inter-observer agreement100,101. However, diagnostic accuracy increases 
when FDG is evaluated in combination with MR imaging (Figure 6)102. Amino acid PET 
radiotracers are useful for the differentiation between treatment related changes 
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and true progression with higher diagnosti c accuracy than standard MR imaging.
[13] Recent studies with a larger glioblastoma pati ent cohort reported a diagnosti c 
accuracy of FET PET of at least 85% for diff erenti ati ng both typical (within 12 weeks) 
and late (> 12 weeks) pseudoprogression aft er radiochemotherapy completi on from 
true tumour progression (Figure 1)54.
Pseudoprogression aft er immunotherapy has been reported using FET PET in a 
small retrospecti ve pilot study in pati ents with malignant melanoma brain metastasis 
treated with ipilimumab or nivolumab103.
TBR, uptake kineti cs and tumour volumes using FET PET have been evaluated for their 
value in monitoring stereotacti c brachytherapy using iodine-125 seeds104. FET PET cor-
rectly diff erenti ated with a high diagnosti c accuracy late postt herapeuti c eff ects aft er 
6 months from local tumour progression in pati ents with recurrent high-grade glioma.
Comparison/combination of methods
Perfusion-derived and PET-derived measures are considered the most reliable when 
it comes to discerning tumour from radiati on necrosis. ASL may be preferable over 
Figure 6. Pati ent with GBM studied before and aft er treatment (radiotherapy with concomitant 
temozolomide, and additi onal 6 cycles of temozolomide). An area of contrast enhancement on the 
T1w MR imaging sequence is observed in the anterior part of the cavity; there is only mild MET 
uptake (TBR=1.7; signifi cantly lower than initi al residual tumour with TBR= 2.6), consistent with 
radiati on necrosis.
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DSC-perfusion imaging because it does not suffer from T1 leakage effects and it al-
lows for quantitative measurement of CBF97.
In clinical practice a combination of MR imaging sequences are used and they 
can be complementary. When the diagnosis is unclear based on MR imaging alone, 
PET-imaging can be considered. An ideal situation would be to use hybrid PET-MR 
imaging. Information on tissue perfusion, cellularity, integrity of neurons, anaerobic 
glycolysis during hypoxia, status of cellular membranes and metabolic pathways can 
then be acquired in one setting5.
Angiogenesis inhibitors and pseudoresponse
Background
Angiogenesis inhibitors, such as the VEGF-inhibitor bevacizumab, are now used in 
variety of tumours including (recurrent) glioblastoma and meningioma. In addition, 
bevacizumab is now used to alleviate oedema surrounding the tumour, but also 
oedema due to radiation necrosis. Due to vascular normalisation ‘leaky’ tumour 
vasculature is normalised and new vessel growth is inhibited. This not only reduces 
oedema but also reduces or even complete dissolution of tumour enhancement. This 
phenomenon is known as pseudoresponse because the tumour may still present107.
With radiation necrosis already difficult to distinguish from residual or recurrent 
tumour, the addition of angiogenesis inhibitors further complicates image interpre-
tation as it can mask the tumour as well as reduce radiation necrosis effects. Varying 
or mixed response to the treatment between patients further plays a confounding 
role108,109. In the context of treatment for radiation necrosis, patients responding to 
bevacizumab treatment only infrequently show recurrence or progression of radia-
tion necrosis after discontinuation110.
PET imaging
The problem of accurately identifying non-enhancing tumour (pseudoresponse) has 
been investigated using amino acid PET to assess treatment response to antiangio-
genic therapy111. Recent studies and case reports indicate that FET and FDOPA PET 
are useful in the context of pseudoresponse both detecting and ruling out the pres-
ence of tumour54. FET and FDOPA PET have also been used to predict a favourable 
outcome in responders to bevacizumab54.
A cost effectiveness analysis of FET PET for therapy monitoring of antiangiogenic 
therapy suggests that the combined use of MR imaging and FET PET in the manage-
ment of these patients have the potential to avoid overtreatment and corresponding 
costs, as well as unnecessary patient side effect112.
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late effects of radiotheraPy
In addition to radiation necrosis, radiotherapy has other late effects on the brain pa-
renchyma, including demyelination, vascular abnormalities and atrophy. Radiation-
induced tumours and malignant transformation have also been reported87,113. The 
extent of these effects is related to total radiation dose, field size, number of fractions 
and frequency, chemotherapy and other medication (methotrexate, corticosteroids, 
anti-epileptic drugs), patient survival and age at the time of radiation therapy87.
White matter abnormalities
White matter is rich in glial cells, such as oligodendrocytes, which are more sensitive 
to radiation than neurons43. White matter damage is a common finding in irradi-
ated patients and includes reactive gliosis, inflammation, oedema, demyelination, 
atrophy, coagulative necrosis, cavitation/cysts and calcification87,114. These different 
entities are difficult to distinguish on histological data and practically impossible to 
differentiate with MR imaging. White matter damage is visible as atrophy and/or 
T2w/FLAIR hyperintensity, also known as leukoencephalopathy87,92. The damage can 
be limited to small discrete lesions or there can be large confluent areas.
Radiation-induced damage to the white matter starts to appear on T2w/FLAIR im-
ages just months after treatment and is generally more severe in older patients113. 
Areas with limited blood supply, such as the periventricular white matter, are affected 
more than for instance the arcuate fasciculus which also receives cortical arterial 
supply88,89. Before abnormalities are visible on the T2w/FLAIR images, DTI can already 
pick up changes in white matter, using parameters such as MD, FA, and diffusivity 
perpendicular and parallel to the white matter fibres115. It has been postulated that 
some of these observed changes may be reversible116.
Grey matter abnormalities
Because neurons are less sensitive to radiation than glial cells the grey matter is 
generally less affected than white matter. Effects that occur are cortical thinning, 
irregularity within the cortex (visible as T2w-hyperintensity) and blurring of the grey 
matter white matter junction92,117. Both grey and white matter damage can result in 
cognitive decline with deficits in learning, working memory and executive functions. 
Symptoms are more prominent when specific areas, such as the hippocampus and 
corpus callosum, are damaged118.
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Figure 7. 35-year old woman treated for medulloblastoma 14 years ago. Aft er subtotal resecti on, 
the tumour was irradiated (57.5Gy) and there has been no recurrent disease. T1w-image shows 
post-operati ve eff ects in the posterior fossa (A). The T2* (gradient echo) sequence shows multi ple 




Direct damage to endothelial cells leads to an increase in permeability, vasogenic oe-
dema, ischemia and hypoxia. Complications that develop after four months include 
lacunar infarcts, microbleeds, large-vessel occlusions with moya-moya syndrome, 
(capillary) teleangiectasias, cavernomas (Figure 7), and stroke86.
A rare late complication after radiotherapy is the so-called SMART syndrome: 
Stroke-like Migraine Attacks after Radiation Therapy (Figure 8). Patients have tran-
sient clinical symptoms and radiological findings suggestive of tumour recurrence 
such as unilateral enhancement of the cortex and T2w-hyperintense white matter. 
The posterior regions of the brain is predominantly involved. The effects are revers-
ible119.
Radiation-induced tumours and malignant transformation
A radiation-induced tumour is a new tumour that grows within the radiation field 
and different histology from the original tumour. Tumours most often encountered 
are meningiomas, followed by glioma and sarcoma87,113. The reported incidence 
of radiation-induced tumours is 2.6% in irradiated children. In adults however, the 
incidence is much lower87,120.
Malignant transformation of meningioma due to irradiation is disputed. The re-
ported incidence is 2.2%, but since malignant transformation of meningioma can 
also occur in the absence of radiotherapy, the true incidence is probably lower. Ves-
tibular schwannoma has been reported to undergo malignant transformation due to 
radiation therapy in 0.3% of cases73,121.
PET imaging
Treatment effects may decrease FDG uptake in the treatment area as well as in brain 
regions that receive synaptic input from the treated area.
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Figure 8. 43-year old male with oligodendroglioma initi ally treated with radiotherapy (50.4Gy) 6 
years previously and with chemotherapy at progression 4 years later. T1w post-contrast (A), FLAIR 
(B), and rCBV (C) aft er therapy show stable residual abnormaliti es. The pati ent subsequently devel-
oped headaches and disorientati on. On the T1w post-contrast image there is enhancement of the 
cortex (D) adjacent to the FLAIR hyperintense area (E). rCBV is increased in the enhancing area (F). 
At 2 months’ follow-up imaging fi ndings had regressed (G, H, I). Symptoms and imaging fi ndings 
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Background. The current method for assessing progressive disease (PD) in glioblas-
toma is according to the Response Assessment in Neuro-Oncology (RANO) criteria. 
Bevacizumab-treated patients may show pseudo-response on post-contrast T1w, 
and a more infiltrative non-enhancing growth pattern on T2w/FLAIR-images. We 
investigated whether the RANO criteria remain the method of choice for assessing 
bevacizumab-treated recurrent glioblastoma when compared to various volumetric 
methods.
Methods. Patients with assessable MRI-data from the BELOB-trial (n=148) were 
included. Patients were treated with bevacizumab, lomustine, or both. At first and 
second radiological follow-up (6 and 12 weeks) PD was determined using the 2D 
RANO criteria and various volumetric methods based on enhancing tumor only and 
enhancing plus non-enhancing tumor. Differences in overall survival (OS) between PD 
and non-PD patients were assessed with the log-rank test and a cox-model. Hazard 
ratios (HR) and their 95% confidence-intervals were determined.
Results. For all patients together, all methods (except subtraction of non-enhanc-
ing from enhancing volume at first follow-up) showed significant differences in OS 
between PD and non-PD patients (p<.001). The largest risk-increase for death in 
case of PD at both first and second follow-up was found with the RANO criteria: 
HR = 2.81 (95% CI, 1.92-4.10) and HR = 2.80 (95% CI, 1.75-4.49) respectively. In the 
bevacizumab-treated patients, all methods assessed showed significant differences 
in OS between PD and non-PD patients. There were no significant differences be-
tween methods.
Conclusions. In the first 12 weeks, volumetric methods did not provide significant 
improvement over the RANO criteria as a post-treatment prognostic marker.
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Importance of study
Currently, the 2D RANO criteria are the method of choice for assessing progres-
sive disease in glioblastoma. However, those treated with bevacizumab may show 
pseudo-response on post contrast T1w-images and non-enhancing tumor growth on 
T2w/FLAIR-images upon progression that may not optimally be captured with the 2D 
RANO criteria. We compared the 2D RANO criteria with various volumetric methods 
based on enhancement, subtraction and T2w/FLAIR abnormalities in this distinct 
patient group. The risk increase for death was determined based on the presence of 
progressive disease upon follow-up. The largest hazard ratios (HR) at first and second 
follow-up were found with the 2D RANO criteria: HR = 2.81 (95% CI, 1.92-4.10) and 
HR = 2.80 (95% CI, 1.75-4.49) respectively. We found no clear differences in predic-
tion of overall survival between the 2D RANO and volumetric methods. The routine 





Glioblastoma is the most common malignant primary brain tumor, comprising 15% 
of all primary brain and central nervous system tumors and almost half of all primary 
malignant brain tumors. The 5-year survival rate is only about 5% despite treatment 
of newly diagnosed patients with surgery, radiotherapy and concomitant and adju-
vant temozolomide1,2.
In 2009, the United States Food and Drug Administration (FDA) approved bevaci-
zumab (Avastin®, Genentech, San Francisco) for second-line treatment in patients 
with recurrent glioblastoma based on the observed response rates from phase 2 
trials with bevacizumab and irinotecan3,4. Bevacizumab is a humanized monoclonal 
antibody directed against Vascular Endothelial Growth Factor (VEGF), which inhibits 
angiogenesis and normalizes abnormally permeable tumor blood vessels5,6. This 
may also lead to a decrease (or complete disappearance) of enhancing tumor on 
post-contrast T1w-images without actual changes in tumor size. Due to this phe-
nomenon of pseudo-responses the conventional MacDonald assessment criteria6, 
that rely primarily on the assessment of enhancing lesions, were no longer sufficient 
and have been replaced by the Response Assessment in Neuro-Oncology or RANO 
criteria7. These have become the standard in clinical neuro-oncology and include the 
assessment of T2w/FLAIR (non-enhancing) abnormalities in addition to enhancing 
lesions. Progressive disease (PD) is defined as a ≥25% increase in the sum of the 
products of perpendicular diameters of enhancing tumor, a significant increase in 
non-enhancing tumor, the appearance of new lesions, or clinical deterioration. It has 
been shown that adding non-enhancing abnormalities based on T2w/FLAIR imaging 
to the response assessment in recurrent glioblastoma treated with bevacizumab may 
lead to earlier detection of PD8.
Despite the inclusion of T2w/FLAIR assessment into the RANO criteria, the main 
focus of response evaluation remains on enhancing tumor. The observed initial 
decrease of enhancing tumor and increase in T2w/FLAIR abnormalities at progres-
sion9,10 in patients treated with bevacizumab suggests that more advanced methods 
of assessment, such as volumetry, might improve prediction of overall survival (OS). 
This is particularly relevant to the assessment of T2w/FLAIR abnormalities, since 
it is defined as a qualitative, and not a quantitative change in volume. Volumetric 
assessments are likely to increase precision of measurements of enhancement in 
irregularly shaped tumors, such as glioblastoma, and T2w/FLAIR abnormalities are 
likely to be more reliably assessed quantitatively with volumetry.
The occurrence of pseudo-response, i.e. the decrease of tumor enhancement 
due to vascular normalization rather than a true anti-tumor effect in glioblastoma 
patients treated with VEGF inhibitors, has now been well documented and questions 
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arise whether further improvement of the RANO criteria is needed. Several studies 
have investigated the evaluation of tumor response using volumetric measures from 
both enhancing and non-enhancing recurrent glioblastoma treated with bevaci-
zumab9,11,12. Boxerman et al13 also directly compared 2D with volumetric methods in 
this specific patient group but did not assess the full RANO criteria. Ultimately, to be 
a reliable surrogate endpoint in phase I and II studies, response should reflect OS, the 
gold standard in oncology trials. Our aim was to determine whether in bevacizumab-
treated recurrent glioblastoma volumetric methods are superior to the 2D RANO 
criteria in determining PD in association with OS.
For this purpose we used data from the BELOB-trial, which is the first randomized 
and properly controlled phase 2 trial in recurrent glioblastoma, comparing single-
agent bevacizumab or lomustine with bevacizumab plus lomustine14.
methods
Patients
A total of 148 eligible patients with first recurrence of glioblastoma were included 
in the BELOB-trial, a randomized controlled phase 2 trial in which patients received 
bevacizumab (Avastin®) (n=50), lomustine (n=46) or both (n=52). Patients were 
recruited between December 2009 and October 2011 from 5 University hospitals 
and 9 community hospitals in the Netherlands. Patients were at least 18 years of age 
and had received no prior treatment with anti-VEGF or nitrosoureas. All patients pro-
vided written informed consent according to national regulations. A more detailed 
description of the study and its findings can be found in Taal et al. 201414.
The primary endpoint of the BELOB trial was 9-month OS. Additional outcome 
measures were median progression-free survival (PFS), PFS at 6 and 12 months, me-
dian OS, OS at 6 and 12 months, and proportion of patients with objective response. 
In the current radiological analysis, OS was used as the endpoint.
Scanning procedure
Patients underwent standardized MRI scanning at baseline and follow-up with ap-
proximately 6-week intervals, i.e. a follow-up scan was made after every treatment 
cycle. The standardized MRI protocol can be found in the Supplementary Files. 
Imaging was performed at 1.5T and 3.0T scanners. During the study, MRI quality as-
sessment was performed. Unfortunately, some patients still had incomplete imaging 




The presence of PD was determined with the 2D RANO method (method 1) and 4 
volumetric methods: total contrast-enhancing (CE) volume measured on T1w post-
contrast images only (method 2), total CE volume measured on subtraction (post-
contrast minus pre-contrast) images only (method 3), total CE volume (as measured 
on T1w post-contrast images) complemented with non-enhancing volume measured 
on FLAIR images (method 4), and total CE volume as measured on subtraction images 
complemented with non-enhancing volume (method 5).
RANO assessment to establish PD was performed centrally (pre- and post-contrast 
T1w- and T2w/FLAIR-images) by 2 independent reviewers (MB, MS). In case of dis-
agreement, PD was decided by an adjudicator (BJ).
Volumes of enhancing areas and non-enhancing (FLAIR) abnormalities were 
measured on 3D T1w post-contrast and 3D FLAIR images, respectively, by a single 
rater (RG) using a semi-automated technique in BrainLab I-Plan 4.0 Cranial (BrainLab, 
Feldkirchen, Germany) software. This technique involves the manual placement 
of ‘inclusion’ and ‘exclusion’ points (Figure 1), after which an algorithm is used to 
render a volume of interest (VOI). All VOIs were visually checked in three directions 
and adjusted if needed.
In each scan, in case of more lesions all lesions were measured separately and 
summed for the current analysis to obtain a single volumetric measure of both the 
enhancing tumor and one of FLAIR abnormalities. Blood vessels, dura and necrotic 
areas were excluded. Enhancing areas were included in the FLAIR VOIs, because 
these areas are also hyperintense on FLAIR. The commonly T2w-hyperintese cortical 
Figure 1. Example of segmentation in BrainLab I-Plan 4.0 Cranial using inclusion (green) and exclu-
sion (blue) lines/points in the axial plane (A) and the resulting segmentation (B).
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ribbon was excluded. Lesions clearly of vascular origin and periventricular apical cap-
ping (i.e. not continuous with FLAIR lesions and remaining unchanged in time) were 
excluded, as well as the septum pellucidem. FLAIR abnormalities when present in 
both left- and right hemispheres were measured separately when possible.
Subtraction images were created with FSL-FLIRT (FMRIB Software Library, Oxford, 
England) with custom scripts in AFNI (National Institute of Mental Health, Bethesda) 
created by Ellingson et al15. VOIs of resulting enhancing tumor areas were drawn 
manually in MRIcron (Chris Rorden, www.mrico.com, version 6.6.2013) by a single 
rater (RG). Necrotic areas, blood vessels and dura were excluded.
PD was defined according to the 2D RANO criteria (as described earlier) for method 
1. For the volumetric methods (methods 2-5), PD was defined as ≥40% increase in 
enhancing/subtraction volume, which was the most commonly used threshold in 
previous literature16-18, ≥25% increase of FLAIR volume19, or the appearance of new 
lesions, whether enhancing or non-enhancing. The 40% threshold for volumetric 
assessment is based on an extrapolation from the ≥25% increase in the sum of per-
pendicular diameters of a 2D lesion to a 3D sphere-shape and the assumption that all 
increase in size is equal in every direction. Setting the threshold this high will ensure 
that only patients showing clear PD are categorized as such.
Statistical analysis
Patients were classified as to PD or non-PD according to each of the 5 methods at both 
first and second follow-up scans. For each of the follow-up moments separately, OS 
was determined from the date of the scan to death from any cause. Patients still alive 
at last contact were censored. Kaplan-Meier survival curves were drawn from each 
follow-up time points for all patients from all treatments groups, as well as for patients 
treated either with bevacizumab (with/without lomustine) or lomustine separately. 
A log-rank test was used to determine the difference in OS between the PD and 
non-PD patients as established by each of the methods. To determine whether there 
were significant differences between methods in predicting OS, hazard ratios (HR) 
and their corresponding 95% confidence intervals (CI) were determined by means of 
a cox regression analysis per method, using each method as a single covariate. The 
HR was determined for all patients together and for the different treatment groups 
per method. The overlap of the corresponding 95% CIs was determined and conclu-
sions were drawn based on the extent of overlap. Statistical analysis was performed 
using SPSS Statistics for Windows (IBM Corp. 2012, Version21.0, Armonk, NY).
A post-hoc power analysis (G*Power20) was performed for all patients together and 
for the two different treatment groups per method at both first and second follow-up 





148 patients were included in the BELOB-trial. At first follow-up 10 patients were 
excluded from the analysis due to a lack of follow-up and missing data required for 
2D RANO assessment. Some further patients had missing 3D T1w pre- and/or post-
contrast or 3D FLAIR images, resulting in the following numbers of patients available 
for analysis at first follow-up: n=138 for method 1, n=121 for method 2, n=86 for 
method 3, n=109 for method 4, and n=89 for method 5. At second follow-up, at 
which time patients with prior PD or death had dropped out, the following numbers 
of patients with adequate imaging were available for analysis: n=83 for method 1, 
n=78 for method 2, n=71 for method 3, n=71 for method 4, and n=67 for method 5.
Assessment of all patients from all treatment groups
Significant differences in OS (Figures 2 and 3) were found between all patients with 
PD and non-PD as determined with methods 1, 2, 4 and 5 at first follow-up, and 
with all 5 methods at second follow-up (Table 1). At first follow-up the highest risk 
increase for death was found for PD as determined with method 1, i.e. the RANO 
criteria, with an HR of 2.81 (95% CI, 1.92 – 4.10). In comparing the methods, the 
extent of overlap in CIs (>50%) indicates that there are no significant differences in 
HR. At second follow-up the highest risk increase was again found for PD determined 
with the RANO criteria (method 1), with an HR of 2.80 (95% CI, 1.75 – 4.49). Again, no 
significant differences were observed between methods as determined by the extent 
of overlap in CIs. For a graphic depiction of the direct comparison between the HRs 
and 95% CI we refer to the Supplementary Files (figure S1).
Assessment per treatment group
The post-hoc power analysis showed that power in the lomustine-only patient group 
was well below 80%, precluding meaningful analysis. Within the bevacizumab-
treated group, power was also insufficient for a meaningful analysis at first follow-
up for method 3 and at second follow-up for methods 2, 3 and 5. Differences in 
Table 1. Hazard ratios of each of the methods for all patients at first and second follow-up (FU1 and FU2).
Method HR (95% CI) FU1 p-value HR (95% CI) FU2 p-value
1. 2D RANO 2.81 (1.92 – 4.10) < .001 2.80 (1.75 – 4.49) < .001
2. Contrast enhancing volume 1.99 (1.29 – 3.05) .002 2.17 (1.27 – 3.71) .004
3. Subtraction volume 1.80 (0.99 – 3.26) .054 2.16 (1.27 – 3.68) .005
4. Contrast enhancing + FLAIR volume 2.45 (1.60 – 3.74) <.001 2.57 (1.53 – 4.31) <.001
5. Subtraction + FLAIR volume 2.66 (1.61 – 4.38) <.001 2.48 (1.47 – 4.18) .001
71









































































































































































































































































































Comparison of 2D and volumetric methods in glioblastoma
power between methods can be attributed to a difference in the number of patients 
available for analysis per method as well as differences in the number of patients 
classified as PD and non-PD.
In the bevacizumab-treated group significant differences in OS (Figure 4) were 
found between patients with PD and non-PD as determined with methods 1, 2, 4 
and 5 at first follow-up, and with methods 1 and 4 at second follow-up (Table 2). The 
highest risk increase at first follow-up was found for PD as determined with method 
2 (i.e. CE volume), with an HR of 7.21 (95% CI, 3.20 – 16.22). This was however not 
significantly different from other methods. At second follow-up only the results from 
methods 1 (i.e. RANO criteria) and 4 (i.e. combined analysis of CE and FLAIR volume) 
were deemed reliable (i.e. power >80%), with HRs of 2.44 (95% CI, 1.46 – 4.08) and 
2.08 (95% CI, 1.16 – 3.73) respectively. These were not significantly different from 
each other. For a graphic depiction of the direct comparison between the HRs and 
95% CI we refer to the Supplementary Files (Figure S1).
Concordance between methods
Concordance rates between method 1 (2D RANO) and the volumetric methods (2-5) 
at first follow-up in all patients together and in the bevacizumab-treated group var-
ied between 81.3% and 87.4%. For a more detailed report and individual examples 
we refer to the Supplementary Files (table S1 and Figures S2 and S3). There are 
several underlying reasons for discrepancies between methods in individual cases. 
The main reasons were: a) PD based on the increase of FLAIR abnormalities, which 
was not picked up using methods 2 and 3 (enhancing/subtraction volume), b) PD 
determined in 2D RANO based on mixed response, not picked up with volumetric 
methods because change in total (non-) enhancing volume was analyzed, c) lesions 
that did not reach the threshold for PD in volumetry (≥40% increase), while having 
reached the threshold for PD in 2D RANO (≥25% increase), and d) significant increase 
in FLAIR volume in volumetry (≥25% increase), not scored as significant in 2D RANO 
(no threshold).
Table 2. Hazard ratios of methods with sufficient power (>80%) for bevacizumab-treated patients 
only at first and second follow-up (FU1 and FU2).
Method HR (95% CI) FU1 p-value HR (95% CI) FU2 p-value
1. 2D RANO 5.53 (3.12 – 9.80) <.001 2.44 (1.46 – 4.08) .001
2. Contrast enhancing volume 7.21 (3.20 – 16.22) <.001
4. Contrast enhancing + FLAIR volume 5.94 (3.06 – 11.53) <.001 2.35 (1.32 – 4.19) .004
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discussion
We investigated whether PD, as determined with various MRI-based methods, was 
associated with OS, the gold standard in oncology studies, in order to identify the 
optimal method for radiological treatment response assessment, in particular in the 
context of anti-angiogenic treatment of recurrent glioblastoma. Currently, the 2D 
RANO criteria are the established method of choice for determining PD in studies 
on glioblastoma. We found that in patients with recurrent glioblastoma treated with 
bevacizumab determining PD with volumetric methods, with or without subtraction, 
did not provide significant improvement as a post-treatment prognostic marker at 6 
and 12 weeks follow-up. The volumetric methods assessed were based on enhanc-
ing lesions only (methods 2 and 3) or on the combined analyses of enhancing and 
FLAIR lesions (methods 4 and 5). The volumetric methods were also not significantly 
different from each other. In the past, several studies on the added value of volum-
etry in recurrent glioblastoma in determining OS have been performed11, 21,22, most 
notably by Boxerman et al.13, in which a direct comparison is made between 2D and 
volumetric methods. We analyzed all patients together and the bevacizumab-treated 
patients separately. Both these analyses failed to show significant differences be-
tween methods. The lomustine-only group comprised one-third of all patients, but 
because this group was too small to draw reliable conclusions from separate analysis, 
its influence on the analysis of all patients together is unclear. This is however of less 
importance, since our main goal was to look at the added value of volumetry (and 
subtraction) in bevacizumab-treated patients. A larger dataset would be required to 
draw definitive conclusions about lomustine treated patients.
Comparisons between 2D (and other linear) and volumetric measures have been 
investigated extensively in a whole range of different tumors23-25, including glioma, 
with contradictory results. Dempsey et al. compared 1D, 2D and volumetric mea-
surements of enhancing volume of high-grade gliomas and found only volumetry to 
be predictive for OS26. Shah et al. on the other hand compared linear measures with 
volumetry and found these comparable when correlated with median progression-
free survival (mPFS), but found linear methods superior when correlated with OS24. 
Galanis et al. compared 1D, 2D, area, and volume-measures of enhancing (and non-
enhancing) newly diagnosed gliomas and found with a time-dependent Cox model 
that PD measured by all four methods was predictive of OS in enhancing tumors27. 
Boxerman et al. compared 2D and volumetric measurements of enhancement and 
the added value of non-enhancing volume in recurrent glioblastoma treated with 
bevacizumab plus a chemotherapeutic agent and found that 2D and volumetric mea-
surements were equally good at predicting OS based on PD at 8 and 16 weeks13. Our 
results are in accordance with these findings. The main differences between their 
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and our studies are that we compared the current golden standard, i.e. the 2D RANO 
criteria, with various volumetric methods including subtraction, and that our study 
had three different treatment arms. It must be noted that the 2D (RANO) assess-
ment of our study was performed by raters with extensive clinical experience, i.e. a 
neuro-oncologist and two neuro-radiologists. This may have had a positive influence 
on the performance of the 2D method in predicting OS. Semi-automated volumetric 
assessment was performed by a single rater. Previous studies have however shown 
inter- and intra-rater variability to be lower in computer-assisted (volumetric) meth-
ods when compared to (non-automated) diameter methods17,28.
Aside from an early pseudo-response, bevacizumab-treated glioblastoma patients 
have also shown an increase of T2w/FLAIR abnormalities at progression9,29. This non-
enhancing tumor progression is likely due to the cooption of blood vessels by tumor 
cells, along which the tumor infiltrates to more distant areas30. The 2D RANO criteria 
adopted a subjective approach for assessing T2w/FLAIR abnormalities. Volumetric 
methods assessing T2w/FLAIR are potentially better suited to quantify these abnor-
malities, especially in view of the often complex shape of glioblastoma. We assessed 
the added value of volumetric FLAIR measures to the enhancement (and subtraction) 
measures and found no differences with the 2D RANO criteria. We did not assess 
FLAIR volume separately, because previous research suggests that volumetric FLAIR 
measures alone are insufficient for predicting OS. Ellingson et al. for instance found 
that FLAIR volume (initial, residual, and change) was not predictive of either PFS or 
OS11. Similarly, Schaub et al. determined that PD on FLAIR measures alone was not 
predictive of OS22. Huang et al. found a correlation between post-treatment T2w/
FLAIR volume and OS, but this correlation disappeared when corrected for enhancing 
volume20.
In addition to measuring enhancing tumor volume on T1w post-contrast and 
non-enhancing tumor volume on FLAIR images, we measured enhancing tumor 
volume on subtraction images. Patients treated with bevacizumab may develop 
T1 hyperintense lesions in a previously enhancing area with a reported prevalence 
between 20 and 80%15,31-33. These lesions likely represent calcifications31. The pres-
ence of T1 hyperintensities might hinder assessment of residual enhancement. Also, 
enhancement may become more vague, interfering with measurement. Ellingson 
et al. found that subtraction images improved visualization, tumor volume quanti-
fication and prediction of OS in patients with recurrent glioblastoma treated with 
bevacizumab in comparison to T1w post-contrast images15. We found that prediction 
of OS by assessing PD on subtraction (method 3) and subtraction plus FLAIR volumes 
(method 5) was similar to that with methods not using subtraction techniques. It 
must be noted that the number of scans suitable for this analysis was limited due to 
the multicenter study designs with hospitals using scanners from different vendors, 
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with varying data quality and protocol violations. This was especially problematic for 
subtraction methods, because matching 3D pre- and post-contrast T1w images were 
commonly not available. Unfortunately, this meant that not all subtraction-based 
methods could be reliably assessed in the bevacizumab-treated patient group. These 
technical shortcomings unfortunately resemble the real life conditions under which 
clinical trials are being conducted. The recently published standardized MRI brain 
tumor imaging protocol should overcome some of these technical difficulties34.
There are several important considerations when designing novel ways to assess 
outcome in phase I and phase II trials. First and foremost, they must correlate with 
the final endpoint used in phase III trials, they must be reliable, and they must be 
feasible in large multicenter trials. A new method must bring either a clear benefit in 
being more accurate, or it must bring an advantage in being simpler but with a simi-
lar precision. Volumetric assessment is more precise in irregularly shaped tumors, 
but labor intensive, time-consuming and more complex, also in the case of semi-
automated techniques. It is also not readily available in many institutions. Our data 
suggest volumetric assessment is not better as compared to classical 2D assessment. 
Therefore, there seems to be no rationale at this point to start using volumetric as-
sessment in trials on recurrent glioblastoma.
There are some limitations to consider in this retrospective study. As previously 
mentioned, rater-experience may have positively influenced the 2D RANO assess-
ment. The interrater variability for assessment according to the 2D RANO from this 
trial will be reported separately. It must also be noted that the volumetry measure-
ments were performed by a single observer. Secondly, our data was analyzed at first 
and second follow-up and presence of PD was determined at these time points only. 
Later follow-up data was not included in this study, because there were not enough 
patients that had not yet shown PD left to obtain reliable results.
Our future efforts are aimed at exploring more advanced imaging techniques, such 
as diffusion imaging-derived apparent diffusion coefficient (ADC) as well as relative 
cerebral blood volume (rCBV) values from enhancing and T2w/FLAIR lesions in 
bevacizumab-treated patients. Additionally, in future exploratory analyses different 
volumetric thresholds for determining PD and a combination of enhancing volume 
plus qualitative FLAIR assessment will be investigated to provide more insight in the 
added value of volumetry in this patient group and that of FLAIR in particular.
We conclude that the current, widely used and easily applicable, 2D RANO criteria 
remain valid for response evaluation in patients with recurrent glioblastoma treated 
with bevacizumab. Volumetric and subtraction evaluation methods failed to yield 
a superior correlation with OS in the first 12 weeks in this patient group. Our data 
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The standardized MRI protocol consisted of the following sequences with full brain 
coverage:
• Pre-contrast three-dimensional (3D) T1-weighted (T1w) IR FSPGR images with 
slice thickness and in-plane resolution ≤1mm.
• Transverse diffusion weighted image (DWI) with slice thickness 3mm (no gap), an 
in-plane resolution of 2mm, and b=0 and b=1000 s/mm2.
• 3D T2-weighted (T2w) fluid attenuation inversion recovery (FLAIR) with slice 
thickness and in-plane resolution ≤1mm and fat-saturation (if possible).
• Transverse 2D T2w image with slice thickness ≤3mm and in-plane resolution 
≤1mm.
• Post-contrast 3D T1w IR FSPGR images with slice thickness and in-plane resolu-
tion ≤1mm.
• Selected sites also performed dynamic susceptibility contrast perfusion imaging: 
transverse gradient echo (GE) echo planar imaging (EPI) perfusion with slice thick-
ness ≤5mm (no gap), an in-plane resolution of ≤3mm, repetition time <2000ms, 
50 phases (100s) with a scan delay of 20s after injection of 10mmol Gd at 4-5ml/s 
followed by 25ml NaCl. A contrast preload bolus of 0.05 Gd mmol/kg body weight 
was given prior to the 3D FLAIR acquisition. In sites not performing perfusion 
imaging, the full contrast bolus was given prior to the 2D T2w image acquisition.
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Figure S2. Discrepant case 1. Pati ent treated with bevacizumab and lomusti ne, scored as no progres-
sive disease (PD) with 2D RANO (method 1) and contrast enhancing volume (method 2), but as PD 
with contrast-enhancing plus FLAIR volume (method 4). Enhancing lesion in left  temporal lobe at 
baseline (A) and fi rst follow-up (B) shows decreasing enhancement (decrease in volume of 13.23%) 
and increasing non-enhancing/FLAIR area at baseline (C and E) and fi rst follow-up (D and F) at two 
diff erent levels (increase in volume of 30.94%). The threshold for PD based on T2w/FLAIR volume 
increase is set at 25%. Black arrows indicate increasing FLAIR abnormaliti es.
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Figure S3. Discrepant case 2. Pati ent treated with lomusti ne, scored as progressive disease (PD) 
with 2D RANO (method 1), but as non PD with contrast enhancing volume (method 2) and contrast-
enhancing plus FLAIR volume (method 4). Enhancing lesion in the left  temporal lobe at baseline (A) 
and fi rst follow-up (B) with limited increase in volume (increase 3.39%) and non-enhancing/FLAIR 
area (increase 6.0%) at baseline (C and E) and fi rst follow-up (D and F) at two diff erent levels. Note 
the diff erences in angulati on between the diff erent ti me points and the poor quality due to moti on 




Table S1. Concordances between method 1 (2D RANO) and the volumetric methods, i.e. method 
2 (contrast enhancing volume), method 3 (subtraction volume), method 4 (contrast enhancing + 
FLAIR volume), and method 5 (subtraction + FLAIR volume) at first follow-up in all patients together 
and in the bevacizumab-treated groups. In case of non-concordance, the presence of progressive 
disease (PD) was more frequently observed with method 1 than with the volumetric methods (2-5).
First follow-up Comparison









All patients Method 1 vs 2 121 101 (83.5%) 16 (13.2%) 4 (3.3%)
Method 1 vs 3 86 76 (87.4%) 9 (10.3%) 1 (1.1%)
Method 1 vs 4 109 91 (83.5%) 10 (9.2%) 8 (7.3%)




Method 1 vs 2 85 70 (82.4%) 12 (14.1%) 3 (3.5%)
Method 1 vs 4 74 61 (82.4%) 6 (8.1%) 7 (9.5%)
Method 1 vs 5 64 52 (81.3%) 7 (10.9%) 5 (7.8%)
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Background. We previously demonstrated that treatment assessment by volumetry 
using a 40% increase threshold for calling progression in recurrent glioblastoma 
treated with bevacizumab did not improve survival prediction compared to standard 
2D methods. However, the optimal volumetric threshold for determining progressive 
disease (PD) has not been defined. We investigated a range of thresholds for enhanc-
ing and non-enhancing tumor volume increase in association with overall survival 
(OS).
Materials and Methods. First recurrent glioblastoma patients treated with be-
vacizumab and/or lomustine were included from the phase II BELOB and phase III 
EORTC26101 trials. Enhancing and non-enhancing tumor volumes were measured at 
baseline, first (6 weeks) and second (12 weeks) follow-up on 3D T1w post-contrast 
and T2w-FLAIR images. Hazard ratios (HRs) for the appearance of new lesions and 
several thresholds for tumor volume increase were calculated using cox regression 
analysis. Results were corrected in a multivariate analysis for well-established prog-
nostic factors.
Results. At first follow-up, 15 patients had a new lesion associated with a sig-
nificantly worse OS (3.2 versus 11.2 months, HR=7.03, p<.001). At first follow-up 
(n=138), lowering the threshold of enhancing volume increase from ≥40% to ≥20% 
increased the HR (from HR=1.77, p=.010 to HR=5.55, p=.001), while only categorizing 
an additional 5 patients as PD. At second follow-up (n=94), lowering the threshold 
from ≥40% to ≥0% also increased the HR (from HR=3.02, p=.001 to HR=9.00, p<.001). 
Assessing the additional effect of measuring non-enhancing volume at first follow-up 
(n=89), the highest HR was found with ≥25% increase in volume (HR=3.25, p=.008).
Conclusion. Early appearing new lesions were associated with poor OS. Lowering 
the volumetric threshold for PD at both first and second follow-up improved survival 
prediction. However, the additional number of patients categorized as PD by lowering 
the threshold was very low. The per-RANO added change in non-enhancing volumes 
to the analyses was of limited value even in the bevacizumab-treated group.
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introduction
Glioblastoma is the most common glioma in adults with an incidence of 0.6-3.7 per 
100,000 persons per year. It has the worst survival rate of all gliomas with a 5-year 
survival of approximately 10% despite intensive surgical, radiotherapy and chemo-
therapy treatment1. Recurrent glioblastoma are often treated with chemotherapy 
and/or angiogenesis inhibitors. Recently, the United States Food and Drug Adminis-
tration has given full approval for use of bevacizumab (Avastin®) in glioblastoma2,3. 
Angiogenesis inhibitors normalize the tumor vasculature, leading to a decrease in 
tumor enhancement on T1-weighted post-contrast images even in the absence of a 
true reduction of tumor activity.
The Response Assessment in Neuro-Oncology (RANO) criteria4 expanded on the 
earlier MacDonald criteria5 by incorporating non-enhancing abnormalities into treat-
ment response assessment. According to the RANO criteria, progressive disease (PD) 
is defined as ≥25% increase in the sum of products of perpendicular diameters of 
enhancing lesions, significant increase in non-enhancing lesions, appearance of new 
lesions, or clear progression of non-measurable lesions. Steroid dosage and clinical 
status are also taken into account. The threshold of ≥25% increase was obtained 
from the World Health Organization response criteria6 and is originally based on 
breast cancer assessment on mammogram7.
Because of their irregular shape in three dimensions and the common presence 
of necrotic areas, it has been postulated that volumetric assessment of glioblastoma 
will improve response evaluation and survival prediction. In addition, volumetric 
methods can help quantify changes in non-enhancing abnormalities, which are cur-
rently assessed only qualitatively with the RANO criteria. On the other hand, upon 
comparing 1D, 2D, and volumetric measures, high concordance between methods 
has been found, questioning the added value of the more demanding volumetric 
assessment8-10. All these studies extrapolated the RANO-based ≥25% increase in 
2D areas to a ≥40% increase in volume (4/3πr3), assuming a sphere-shaped tumor 
equally increasing in all directions11, which foregoes the potential increased sensi-
tivity of volumetric assessment. Some authors have used different volumetric cut-
off values for PD, such as ≥25%12, ≥15%13, and ≥5%14, suggesting that using lower 
thresholds could lead to a better survival prediction. Previously, a ≥25% increase of 
non-enhancing volumes has been proposed as the threshold to establish PD10,15.
We aimed to determine whether lowering the volumetric threshold for PD in both 
enhancing tumor and non-enhancing abnormalities improves survival prediction 
and whether there is a preferred moment for first follow-up. We also evaluated the 





Included in this analysis were patients with first recurrence of glioblastoma treated 
in the phase II BELOB trial (n=148; eligible patients) and the patients treated with 
lomustine at our institution in the subsequent phase III EORTC26101 trial (n=35)16,17. 
Patients from the BELOB trial were randomized to three different treatment arms: lo-
mustine (n=46), bevacizumab (n=50), or both (n=52); patients from the EORTC26101 
trial were randomized to lomustine or bevacizumab plus lomustine. The 35 patients 
from the EORTC26101 trial were all treated with lomustine in the same way as in the 
BELOB trial with similar follow-up measures, and were added to obtain a balanced 
representation of lomustine and bevacizumab-treated patients. Patients were re-
cruited between December 2009 and October 2011 and between October 2011 and 
October 2015 for respectively the BELOB trial and EORTC26101 trial. Patients had 
received no prior treatment with Vascular Endothelial Growth Factor (VEGF) inhibi-
tors or nitrosoureas, were at least 18 years of age and had given informed consent 
according to national guidelines. Further study and patient details can be found in 
Taal et al. 2014 and Wick et al. 2016. The study endpoint in the current analysis was 
overall survival (OS), measured from the moment of follow-up (either first of second) 
to death from any cause.
Standardized MRI scans were performed at 6-week intervals and included pre- and 
post-contrast 3D T1-weighted (T1w) inversion recovery (IR) fast spin gradient recalled 
echo (FSPGR) and 3D T2-weighted (T2w) Fluid Attenuation Inversion Recovery (FLAIR) 
imaging, all with a slice thickness and in-plan resolution ≤1mm. Scans from baseline, 
first, and second follow-up were included in this analysis.
Data processing
Semi-automated segmentation techniques were used to obtain total enhancing and 
total non-enhancing volumes from respectively 3D T1w post-contrast and 3D FLAIR-
images. The BELOB-trial scans were segmented by R.G. in Brainlab iPlan 4.0 Cranial 
and the EORTC26101 scans were segmented by G.K. and R.G. using ITK-SNAP18. Areas 
of necrosis, pre-contrast T1w hyperintensity, blood vessels, and dura were excluded. 
New enhancing and non-enhancing lesions were scored by R.G. at the time of 
performing the segmentation. New lesions of any size were included and in case of 
unclear lesion origin, persistence or increase in size at the next available follow-up 
was taken into account according to the RANO criteria.
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Statistical analysis
Hazard ratios (HRs), 95% confidence intervals (CI) and p-values were calculated with 
Cox regression analysis. All results were corrected in a multivariate analysis for World 
Health Organization (WHO) performance status, steroid use at baseline, number of 
target lesions (0-1 versus ≥2), enhancing tumor volume at baseline, and predomi-
nantly frontal location (if p<.10)19. In the multivariate analysis p<.05 was considered 
significant.
We calculated the association between the appearance of a new lesion at first, 
i.e. 6 weeks’ follow-up with OS. Both enhancing and/or non-enhancing lesions of 
any size that remained stable or increased at the next follow-up were scored. As 
the appearance of a new lesion is considered unequivocal PD, these patients were 
subsequently excluded from the threshold analysis.
Analyses of enhancing and non-enhancing volume thresholds were performed in 
all treatment groups together, and subsequently in the lomustine-only treated and 
in the bevacizumab (with/without lomustine) treated groups separately at both 
first and second follow-up. To determine the association between increasing tumor 
volume and OS, HRs were calculated in strata of ≥40%, ≥20 – <40%, and ≥0 – <20% 
increase in enhancing volume and ≥25%, ≥10 – <25%, and ≥0 – <10% increase in 
non-enhancing volume (from now on referred to as strata 20-40% etc.). The thresh-
old with the highest HR was considered the most predictive for OS. Patients with 
PD based on increasing enhancing volume were excluded from the non-enhancing 
volumetric analysis so that the added values of measuring non-enhancing volumes 
could be determined.




Patients without available 3D T1w post-contrast and FLAIR images at relevant time 
points were excluded from the analyses. Additionally, patients that did not reach first 
(n=4) or second (n=60) follow-up were excluded from analyses at these time points 
(see Figure 1 for included patients per analysis).
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Figure 1. Flow diagram of all pati ents included from the BELOB and EORTC 26101 trials (n=183), rea-
sons for excluding pati ents (in order) per analysis and number of pati ents included in the fi nal analyses.
The four pati ents that did not reach fi rst follow-up within the trial had a median OS 
of 1.5 months measured from baseline to death. Another 60 pati ents did not reach 
second follow-up of which the majority had been randomized to the lomusti ne-
treated group (n=37).
Univariate analyses (Table 1) showed associati ons between OS and WHO per-
formance status (HR=1.67, p<.001), steroid use at baseline (HR=1.60, p=.002), 
predominantly frontal locati on (HR=1.34, p=.061), and enhancing volume at baseline 
(HR=1.02, p<.001). These variables were therefore included in the multi variate analy-
sis. Number of target lesions and age were not associated (p>.10) with OS.
Table 1. Univariate Cox regression analyses of variables with potenti al infl uence on survival, Hazard 
rati os (HRs), 95% confi dence intervals (CIs) and p-values for all treatment groups together and beva-
cizumab- and lomusti ne-treated pati ents separately. Overall survival is measured from randomiza-
ti on to death by any cause.
Parameters
All treatment groups Bevacizumab Lomusti ne
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
WHO performance status 1.67 1.30-2.15 <.001 1.85 1.29-2.65 .001 1.49 1.01-2.12 .028
Steroid use 1.60 1.19-2.15 .002 1.52 1.02-5.56 .041 1.63 1.04-2.55 .032
Number of target lesions 1.09 0.79-1.52 .59 1.17 0.76-1.80 .48 1.07 0.63-1.79 .81
Predominantly frontal locati on1.34 0.99-1.83 .061 1.26 0.84-1.90 .26 1.54 0.95-2.50 .078
Age 1.01 0.99-1.03 .16 1.01 0.99-1.02 .53 1.02 0.99-1.04 .13
Baseline enhancing volume 1.02 1.01-1.03 <.001 1.02 1.01-1.04 .012 1.02 1.01-1.03 .009
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New lesions
At fi rst follow-up (n=179), a new enhancing and/or non-enhancing lesion appeared 
in 15 pati ents (a more detailed descripti on can be found in the Supplementary Files. 
Table S1 and Figure S1). The univariate HR for OS of the development of new lesions 
was highly signifi cant (HR=5.27, p<.001) and increased aft er correcti on for other vari-
ables in a multi variate analysis (HR=7.03, p<.001). The median OS of pati ents with 
a new lesion at fi rst follow-up was 2 months versus 8.5 months in pati ents without 
a new lesion (Figure 2). At second follow-up, 2 additi onal pati ents had developed a 
new lesion (1 enhancing and 1 non-enhancing).
Figure 2. Kaplan-Meier curves of pa-
ti ents with and without a new lesion 
at fi rst follow-up. The median overall 
survival (measured from fi rst follow-
up) was 2 versus 8.5 months, respec-
ti vely.
Enhancing lesions
In all treatment groups combined, pati ents with a ≥ 40% increase in enhancing vol-
ume at fi rst or at second follow-up had a signifi cantly worse OS compared to those 
with less than 40% increase (HR=1.77, p=.010 and HR=3.02, p=.001, respecti vely) in 
the multi variate analysis. Within the threshold stratum of 20–40% increase, an ad-
diti onal 5 pati ents were categorized as PD at fi rst follow-up, and 2 pati ents at second 
follow-up. When lowering the threshold to stratum 0-20% increase, 12 and 6 pa-
ti ents were additi onally categorized as PD at fi rst and second follow-up respecti vely. 
The highest HR at fi rst follow-up was found with stratum 20-40% increase (HR=5.55, 




Table 2. Hazard ratios (HRs), 95% confidence intervals (CIs), and p-values for the strata ≥40%, 20-
40%, and 0-20% increase in enhancing volume at first and second follow-up in all treatment groups 
together and in the lomustine-treated group. Patient numbers with enhancing volume increase in 





First follow-up (n=138) Second follow-up (n=94)
n HR 95% CI p-value n HR 95% CI p-value
All 40 31 1.77 1.15-2.72 .010 12 3.02 1.57-5.79 .001
20-40 5 5.55 2.06-14.91 .001 2 - - -
0-20 12 1.01 0.54-1.90 .97 6 9.00 3.32-24.42 <.001
Lomustine 40 30 1.76 0.99-3.16 .056 8 3.63 1.33-9.87 .012
20-40 4 - - - 2 - - -
0-20 10 0.70 0.28-1.78 .46 5 10.70 3.45-33.17 <.001
In the lomustine-treated group, threshold stratum ≥40% increase and stratum 
0-20% increase could be analyzed. HRs were borderline significant at ≥40% (HR=1.76, 
p=.056) and not significant at stratum of 0-20% increase at first follow-up; at second 
follow-up the highest significant HR was found with the threshold stratum of 0-20% 
increase (HR=10.70, p<.001). The number of patients categorized as PD by increase 
in enhancing volume of strata 20-40% in the lomustine-treated group and ≥0% in the 
bevacizumab-treated group was insufficient for meaningful analysis.
Non-enhancing lesions
To determine the added value of measuring non-enhancing volume increase for 
response assessments, patients with PD based on increasing enhancing volume (at 
thresholds determined based on the highest HR found) were excluded from the 
analyses, i.e. stratum 20-40% at first follow-up. In all treatment groups together, the 
Table 3. Hazard ratios (HRs), 95% confidence intervals (CIs), and p-values for ≥25%, stratum 10-25%, 
and stratum 0-10% increase in non-enhancing volume at first and second follow-up in all treatment 
groups together and in the bevacizumab-treated group. Patient number with non-enhancing vol-
ume increase in the lomustine-treated group was insufficient for meaningful analysis.
Treatment groups
≥% increase  
in volume
First follow-up (n=89)
n HR 95% CI p-value
All 25 6 3.25 1.37-7.70 .008
10-25 5 1.88 0.72-4.86 .196
0-10 8 0.63 0.28-1.39 .248
Bevacizumab 25 5 5.04 1.80-14.08 .002
10-25 2 - - -
0-10 4 - - -
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highest HR was found at a threshold of ≥25% at first follow-up (HR=3.25, p=.008), 
categorizing 6 additional patients as PD. At the same threshold, the HR was also 
significant in the bevacizumab-treated group (HR=5.04, p=.002) (see Table 3). The 
lomustine-treated group could not be analyzed because <5 patients were categorized 
as PD based on non-enhancing volume increase. Analyses of non-enhancing volumes 
at second follow-up could not be performed for the same reason.
discussion
In this analysis of patients with recurrent glioblastoma, PD was determined based 
on the appearance of a new lesion, increasing enhancing volume, and increasing 
non-enhancing volume in association with OS. A new enhancing or non-enhancing 
lesion of any size at early follow-up was significantly associated with poor OS. When 
considering patients with increasing enhancing volumes, the majority of patients 
had an increase of ≥40%. Lowering the threshold to stratum 20-40% increase at 
first follow-up and to stratum 0-20% increase at second follow-up improved survival 
prediction, but only a small number of patients were additionally categorized as PD 
with these lower thresholds.
After excluding all patients with PD based on the appearance of a new lesion or 
increase in enhancing tumor volume, an increase in non-enhancing volumes of ≥25% 
was significantly associated with poorer OS. However, only 6 out of 89 patients (5 of 
whom were treated with bevacizumab) were categorized as PD and thus the added 
value of considering non-enhancing volumes was limited in this population.
HRs at second follow-up (i.e. after 12 weeks) were higher and more significant than 
those at first follow-up (i.e. after 6 weeks). This effect can be largely attributed to the 
lower number of patients included at second follow-up, as many had already reached 
PD (based on either radiological or clinical parameters) prior to this evaluation point. 
This complicates the comparison of these two evaluation points. In the lomustine-
treated group many patients had reached radiological PD after 6 weeks, while in the 
bevacizumab-treated group enhancing tumor volumes did not increase much even 
after 12 weeks follow-up.
While results found in the lomustine-only treated group were similar to those 
found in all treatment groups together, results from the bevacizumab-treated 
group are more difficult to interpret as only a small number of patients showed 
an increase in enhancing tumor volume at 6 and 12-week follow-up. Slightly more 
bevacizumab-treated patients were categorized as PD when non-enhancing volume 
increase was taken into account, confirming a possible role for the RANO emphasis 
on non-enhancing volumes in bevacizumab-treated patients. In previous literature, 
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an increase in non-enhancing abnormalities has been described as a pattern of pro-
gression after anti-angiogenic treatment20,21, but since our data is limited to the early 
period of follow-up, we are unable to determine if this patterns of progression is 
more common in the bevacizumab-treated patients at later stages, and hence what 
the true value of volumetric assessment of non-enhancing abnormalities is during 
the entire course of anti-angiogenic treatment.
We measured total volume of either enhancing or non-enhancing lesions, which 
means that mixed responses were not considered. Mixed response is seen in a 
subset of patients22,23, but we postulate that the outcome of these patients is de-
termined by the overall volume increase or by newly appearing lesions. Measuring 
total non-enhancing volume could also have confounded results, as these volumes 
include tumor, effects due to earlier treatment, and edema. As bevacizumab is a 
known edema-relieving agent24, a decrease in non-enhancing volume in this group is 
expected at early assessment.
The benchmark for increase in volume was overall survival, considered the gold 
standard in oncology trials and the ultimate measure of patient benefit. Results 
were corrected for several known prognostic variables, including baseline enhanc-
ing tumor volume19. The prognostic significance of the latter was conformed in our 
dataset. Initial tumor size is also important to take into account when measuring 
change in size as an increase of ≥25% has a more profound effect in an already large 
tumor compared to a small tumor. Large tumors are not only associated with a worse 
OS, but with worse overall clinical condition as well25.
An important argument in favor of performing volumetric rather than 2D measure-
ment is the lower inter- and intra-rater variability, which has previously been shown 
with (semi-)automated techniques. Unfortunately, volumetric measurement are 
still much more difficult to obtain than the commonly used 2D measures, and their 
added value for response assessment is disputed8-10. Despite the unclear added value 
when it comes to predicting survival, tumor volumes does more accurately reflect 
the – enhancing – tumor size than 2D measurement. Especially in heterogeneous 
tumors such as glioblastoma this could be useful. Furthermore, from such a volume 
of interest, other measures such as Apparent Diffusion Coefficient (ADC) and relative 
Cerebral Blood Volume (rCBV) can also be determined, facilitating a more integrated 
approach to tumor assessment, which would potentially improve survival prediction 
further.
The main limitation of our study is the relatively small sample size of bevacizumab-
treated patients showing progression of enhancing lesions at this early assessment 
time point. Assessment at later time points and/or a larger sample size is desirable 
to further determine the value of volumetric imaging (i.e. looking at enhancing and 
non-enhancing volume) in this treatment group.
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In conclusion, new lesions, whether enhancing or non-enhancing, appearing early 
after the start of treatment were clearly associated with poor outcome. While only 
a small additional number of patients would be categorized as PD with volumetric 
thresholds lower than the commonly applied 40% increase, survival prediction did 
improve and therefore lowering the threshold should be considered. We found no 
added value for measuring non-enhancing volumes in patients treated with lomus-
tine only. In the bevacizumab-treated group early increase in tumor size (either 
enhancing or non-enhancing) was found to be rare. Here, increasing lesions were 
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Figure S1. Examples of new lesions found at fi rst follow-up. New enhancing lesions found in pati ents 
046 (A), 071 (B), and 087 (C) and a new non-enhancing lesion found in pati ent 137 (D). Additi onal 
informati on on these pati ents can be found in TableS1.
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Table S1. Characteristics of all patients with a new lesion at first follow-up (n=15). Enhancing and 












BELOB 004 Bevacizumab Enhancing 0.773 22.1 61
004 Non-enhancing 0.142 11.4
028 Bevacizumab Enhancing 0.019 6.73 220
029 Lomustine Non-enhancing 1.044 17.3 57
046 Bevacizumab+lomustine Enhancing 0.217 10.9 43
071 Lomustine Enhancing 1.388 17.7 32
085 Lomustine Enhancing 0.023 4.77 35
087 Bevacizumab Enhancing 0.016 3.10 114
092 Bevacizumab Enhancing 0.014 5.34 61
100 Lomustine Enhancing 0.022 2.58 198
127 Bevacizumab Enhancing 0.014 2.50 77
137 Bevacizumab Non-enhancing 2.042 22.4 54
151 Bevacizumab Non-enhancing 0.828 15.3 86
151 Non-enhancing 0.328 6.60
EORTC26101 161 Lomustine Enhancing 0.14 5.79 251
180 Lomustine Non-enhancing 14.02 62.0 39
189 Lomustine Enhancing 0.03 4.22 96
189 Enhancing 0.06 3.00
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Purpose: To investigate the value of apparent diffusion coefficient (ADC) histogram 
analysis to predict overall survival (OS) after the first treatment course of bevaci-
zumab and/or lomustine in recurrent glioblastoma.
Materials and Methods: Patients (n=148) were included from the board-approved 
multicenter BELOB-trial and informed consent was acquired. Standardized MRI-scans 
from baseline and 6-week follow-up were retrospectively analyzed. Volumes of 
interest (VOIs) of enhancing and non-enhancing lesions were drawn on 3D T1w post-
contrast and FLAIR images and co-registered with ADC-maps. Patients with missing 
MRI-data or small lesions (<0.2cm3) were excluded. Unimodal ADC-histogram param-
eters were derived per VOI. From exploratory analyses of each histogram parameter 
performed in all treatment groups together, ADCmin was found to be most promising 
in predicting OS and was further analyzed using cox-regression analysis. The optimum 
cut-off value for predicting OS was determined in a multivariate analysis.
Results. Change in ADCmin in enhancing lesions was analyzed in 108 patients. A de-
crease of >27.5% resulted in significantly better OS when looking at all treatment arms 
together (HR=0.572, p=.007), both bevacizumab-treated groups (n=72) (HR=0.452, 
p=.002), and in the combination-treatment arm (n=38) (HR=0.287, p=.001). After 
correcting for WHO performance status, corticosteroid use, and baseline enhancing 
volume, results remained significant: HR=0.482 (p=.001), HR=0.415 (p=.001), and 
HR=0.250 (p<.001) respectively. No significant differences in OS were found in the 
monotherapy arms, nor in the non-enhancing lesions.
Conclusion. Decrease in ADCmin in enhancing recurrent glioblastoma treated with 
bevacizumab and lomustine was associated with significantly better OS.
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Advances in knowledge:
• Response in terms of overall survival can be predicted by measuring change in 
ADCmin values from baseline to first follow-up in recurrent glioblastoma treated 
with bevacizumab combined with lomustine.
• Changes in ADCmin were only predictive for response in terms of overall survival in 
enhancing but not in non-enhancing lesions.
Implication(s) for patient care:
• Where response in recurrent glioblastoma treated with bevacizumab is difficult to 
determine on conventional imaging due to issues with pseudo-response, change 
in ADCmin can help to predict response in terms of improved overall survival after 
the first course of treatment.
Summary statement:
Change in ADCmin values measured in the enhancing portion of recurrent glioblas-
toma predicts improved overall survival at first follow-up after treatment with 
bevacizumab and lomustine when using a cut-off percentage change between -5% 




Glioblastoma multiforme is the most common malignant primary brain tumor with 
a 5-year survival rate of only 5% despite intensive treatment1,2. Based on the results 
from two phase-II trials with bevacizumab (Avastin®, Genentech, San Francisco) and 
irinotecan3,4, the United States Food and Drug Administration (FDA) approved the use 
of bevacizumab for second-line treatment in patients with recurrent glioblastoma 
in 2009. Bevacizumab is an angiogenesis inhibitor that specifically targets Vascular 
Endothelial Growth Factor (VEGF), resulting in the normalization of tumor blood ves-
sels5. This reduces contrast-enhancement, edema, perfusion, and also diffusion6-9.
Response assessment in glioblastoma is formulated in the Response Assessment in 
Neuro-Oncology (RANO) criteria, which are based on change in contrast-enhancement 
and/or non-enhancing abnormalities on T2-weighted (T2w)/Fluid attenuated inversion 
recovery (FLAIR) magnetic resonance (MR) imaging10. Decrease in contrast enhance-
ment and edema in patients treated with bevacizumab may be actual tumor response 
or pseudo-response (i.e. decrease in vascular permeability only). The RANO do not 
discern the cause of the decrease and an imaging marker of true tumor response to 
bevacizumab is at present lacking. With diffusion weighted imaging (DWI), a quantita-
tive measure of the magnitude of diffusion can be obtained, expressed as the apparent 
diffusion coefficient (ADC). Previous studies using histogram analysis of tumor ADC-
values at baseline in patients treated with bevacizumab indicate that low values of ADC 
may be predictive for survival11,12. In bevacizumab-treated patients diffusion restriction 
has been observed after treatment, but the exact meaning of this finding is unclear9,13.
Since not all patients seem to benefit from expensive treatment with bevacizumab, 
discerning the responders from the non-responders at an early stage is important to 
save costs and prevent possible side-effects in non-responders14. While progressive dis-
ease (PD) in bevacizumab-treated patients can be reliably established using the RANO 
criteria, a distinction between responders and non-responders when there is stable 
or decreased contrast enhancement is problematic due to the possibility of pseudo-
response. The purpose of this study was to assess the value of ADC histogram analysis 
to predict overall survival (OS) after the first course (i.e. 6 weeks) of bevacizumab to 
obtain an indication of response at the very early stage after start of treatment.
methods
Patients
Patients from the Dutch institutional review board-approved BELOB trial (148 eligible 
patients), which is a phase II randomized controlled trial of first recurrence glioblas-
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toma treated with either bevacizumab (Avastin, Roche) (n=50), lomustine (n=46) or 
a combination of both (n=52), were analyzed (Nederlands Trial Register, www.trial-
register.nl, number NTR1929). Patients signed informed consent and were included 
between December 2009 and October 2011. No prior treatment with angiogenesis 
inhibitors or nitrosoureas had taken place, instead patients had been treated with 
surgery, radiotherapy and temozolomide. Details on the in- and exclusion criteria as 
well as the findings on the primary outcome from the trial are described elsewhere15. 
Earlier radiological analysis in this same patient population16 did not include analysis 
of the DWI that were acquired during this study. All patients were above the age of 
18, with a mean age of 55.9 years (range 24-77). Outcome measures were 6, 9 and 
12-month OS and the proportion of patients with an objective response. In the current 
analysis OS was measured from first follow-up (i.e. 6 weeks) to death from any cause.
Data acquisition
Patients were treated in 14 different hospitals with follow-up which included MR 
scanning at 6-week intervals according to a standardized MR-protocol. Sequences 
scanned were: pre- and post-contrast 3D inversion recovery (IR) fast spin recovery 
gradient (FSPGR) T1-weighted (T1w) images with slice thickness and in-plane resolu-
tion ≤1mm, 3D T2w-FLAIR with slice thickness and in-plane resolution ≤1mm and 
fat-saturation, and transverse diffusion weighted images (DWI) with slice thickness 
of 3mm (no gap), in-plane resolution of 2mm, and b=0 and b=1000 s/mm2. Due to 
differences in protocol implementation, voxel sizes of the DWI data differed between 
hospitals, ranging from 0.9x0.9x3.0mm to 2.0x2.0x6.0mm. Additionally, the protocol 
consisted of transverse 2D T2w, and dynamic susceptibility contrast perfusion imag-
ing (selected sites only), not used for the current study.
Data post-processing
Enhancing tumor was segmented on T1w post-contrast images, and non-enhancing 
abnormalities on T2w-FLAIR images in BrainLab’s I-Plan 4.0 Cranial using a semi-
automated technique. The resulting volumes of interest (VOI) were categorized as 
enhancing and non-enhancing and assessed separately (Figure 1). T2w-FLAIR and 
DWI images as well as the VOIs were registered to the T1w post-contrast image per 
time-point with a non-linear registration technique using custom scripts in Matlab 
(R2014a) and Elastix17. During this registration the differences in voxel size and 
signal-to-noise ratio (SNR) between the different hospitals are taken into account 
(see Supplementary Files A for the parameter settings used in Elastix). To obtain a 
VOI for the non-enhancing lesion only, the enhancing lesion VOI was subtracted from 
the total non-enhancing VOI. ADC-maps were calculated from the DWI images and 
unimodal ADC-histogram parameters (mean, median, minimum, maximum, stan-
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dard deviation, kurtosis and skewness) were computed from each VOI. A unimodal 
approach was chosen after visual inspection of histograms from 266 lesions at both 
baseline and first follow-up, which showed unimodal distribution in respectively 85% 
and 81% of cases. In case of multiple lesions in a single patient, histogram parameters 
were combined to obtain a single histogram per enhancing and non-enhancing VOI. 
VOIs <0.2cm3 were excluded from analysis.
Figure 1 (A-D): 3D T1-weighted post-contrast and 3D T2w/FLAIR images without (A, C) and with (B, 
D) volumes of interest (VOI) in the same patient. The enhancing VOI was subtracted from the non-
enhancing VOI to obtain the truly non-enhancing portion of the tumor.
Statistical analysis
All statistical analyses were performed using SPSS Statistics for Windows, Version 
21.0 (Armonk, NY: IBM Corp. 2012). First, percentage change between baseline and 
first follow-up (i.e. 6 weeks after start of treatment) was calculated for each ADC 
histogram parameter. Exploratory analyses were then performed in the entire group 
of patients to determine which parameter(s) had potential value in establishing dif-
ferences in OS. For every parameter, the group was dichotomized using its median. 
With cox regression analysis hazard ratios (HR) were obtained (significance level 
p<.05). Exploratory analyses were not performed in the separate treatment arms to 
avoid over-fitting, nor were threshold values chosen at this stage.
After determining which parameters were potentially useful in predicting OS, a range 
of cut-off values for percentage change measured in enhancing and non-enhancing 
lesions separately were tested in the entire group, in those treated with bevacizumab, 
and in all treatment arms separately. For the optimal threshold, results were corrected 
in a multivariate survival analysis (cox regression) for age, WHO performance status, 
corticosteroid use, and baseline enhancing volume (if p<.10 in univariate analysis).
In every patient, baseline and first follow-up scans had been performed in the 
same hospital on scanners from the same vendor. Four patients were scanned at 
different scanner field strengths between baseline and first follow-up (i.e. 1.5T and 
3.0T). To assess the effect of differences in field strength, an additional analysis was 
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performed, correcti ng for diff erences in ADC values, using a factor of -9.79% to cor-
rect the values from the 3.0T scanner18.
results
Patients
Out of 148 eligible pati ents, only those pati ents with 3D T1w post-contrast and/
or T2w/FLAIR images were analyzed. In the analysis of enhancing lesions and non-
enhancing lesions, respecti vely 108 and 99 pati ents were included (see Figure 2).
Histogram analysis
In the exploratory analysis, only skewness (ADCskew) and minimum ADC (ADCmin) showed 
promise in predicti ng OS. Further explorati on of the ADCskew data showed inconsistent 
Figure 2: Flow diagram showing all pati ents included in the BELOB trial and those included in the 
fi nal analyses. Pati ents with 3D T1weighted post-contrast (T1w+C) and 3D FLAIR scans at both base-
line and fi rst follow-up were included. Lesions <0.2cm3 were excluded; if multi ple lesions were pres-
ent within a single pati ent, these were combined in a single volume of interest.
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fi ndings due to multi ple outliers. ADCmin did show consistent signifi cant results and 
further cut-off  values for percentage decrease of this parameter were tested (5%, 
10%, 15%, 20%, 22.5%, 25%, 27.5%, 30%, and 32.5%) in enhancing and non-enhancing 
lesions separately (Supplementary Files: Table S1 and Table S2). Figure 3 shows an 
example of ADCmin histograms at baseline and fi rst follow-up. Other histogram param-
eters explored did not show meaningful correlati ons with OS (data not shown).
Figure 3: Apparent diff usion coeffi  cient (ADC) 
histogram at baseline (bold line) and fi rst fol-
low-up at 6 weeks (do� ed line) in an enhanc-
ing lesion of a pati ent treated with bevaci-
zumab plus lomusti ne. Percentage change in 
ADCmin was -33.64% and the OS 13.3 months.
In enhancing VOIs (n=108), when assessing all treatment groups combined strati fi -
cati on of pati ents based on a decrease in ADCmin of 20% to 30% showed a signifi cant 
diff erence in OS, with the most signifi cant HR found with 27.5% decrease (HR=0.572, 
95% CI 0.38-0.86, p=.007). This result remained signifi cant aft er correcti ng for WHO 
performance status, corti costeroid use, and baseline enhancing volume (HR=0.482, 
95% CI 0.32-0.74, p=.001), see Table 1. In both bevacizumab-treated groups com-
bined (n=72) strati fi cati on of pati ents based on decrease in ADCmin of 10% to 30% 
showed a signifi cant diff erence in OS. The most signifi cant HR was found with 27.5% 
decrease (HR=0.452, 95% CI 0.27-0.75, p=.003), which aft er correcti ng for covari-
ates remained signifi cant (HR=0.415, 95% CI 0.25-0.70, p=.001), see Table 2. Upon 
further dividing the bevacizumab-treated groups into the bevacizumab-only and 
combined treatment arms, the signifi cant diff erences were shown to originate from 
the combined treatment arm (n=38): strati fi cati on of pati ents based on decrease in 
ADCmin of 5% to 27.5% showed a signifi cant diff erence in OS in this pati ent group. 
The most signifi cant HR was again found with 27.5% decrease (HR=0.287, 95% CI 
0.34-0.60, p=.001). Results remained signifi cant aft er correcti ng for corti costeroid 
use (HR=0.250, 95% CI 0.12-0.54, p<.001), see Table 3. The mean OS measured 
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Table 1: Univariate and multivariate assessment of the predictive value of >27.5% decrease in ADC-




Hazard Ratio 95% CI p-value Hazard Ratio 95% CI P-value
>27.5% decrease in ADCmin* 0.572 0.38-0.86 .007 0.482 0.32-0.74 .001
Age 1.003 0.99-1.02 .713
WHO performance status 1.446 1.02-2.05 .039 1.424 0.94-2.16 .096
Corticosteroid use 1.551 1.05-2.28 .026 1.010 0.62-1.64 .968
Baseline enhancing volume 1.022 1.01-1.04 .006 1.026 1.01-1.04 .003
*ADCmin = minimum apparent diffusion coefficient; WHO = world health organization; CI=confidence in-
terval
Table 2: Univariate and multivariate assessment of the predictive value of >27.5% decrease in ADC-
min in enhancing lesions in both bevacizumab-treated groups (n=72)
Both bevacizumab-treated groups (n=72)
Variables
Univariate Multivariate
Hazard Ratio 95% CI p-value Hazard Ratio 95% CI p-value
>27.5% decrease in ADCmin* 0.452 0.27-0.75 .002 0.415 0.25-0.70 .001
Age 1.005 0.99-1.03 .611
WHO performance status 1.456 0.94-2.25 .090 1.417 0.85-2.36 .181
Corticosteroid use 1.677 1.04-2.69 .033 1.213 0.69-2.14 .503
Baseline enhancing volume 1.021 1.00-1.04 .038 1.017 0.99-1.04 .118
*ADCmin = minimum apparent diffusion coefficient; WHO = world health organization; CI=confidence in-
terval
Table 3: Univariate and multivariate assessment of the predictive value of >27.5% decrease in AD-
Cmin in enhancing lesions in the combined treatment arm (i.e. lomustine and bevacizumab) (n=38).
Bevacizumab + lomustine (n=38)
Variables
Univariate Multivariate
Hazard Ratio 95% CI p-value Hazard Ratio 95% CI p-value
>27.5% decrease in ADCmin* 0.287 0.14-0.60 .001 0.250 0.12-0.54 <.001
Age 1.003 0.98-1.03 .836
WHO performance status 1.329 0.74-2.40 .344
Corticosteroid use 1.807 0.92-3.55 .085 2.139 1.07-4.29 .033
Baseline enhancing volume 1.015 0.99-1.04 .264




from fi rst follow-up was 15.2 months in pati ents with a decrease in ADCmin ≥27.5% 
(n=24), versus 6.8 months in those with a decrease of ADCmin <27.5% (n=14). In the 
bevacizumab or the lomusti ne monotherapy group, no signifi cant diff erences in OS 
were seen at any of the cut-off  values. Aft er correcti on for diff erences in scanner fi eld 
strength between baseline and follow-up in four pati ents, strati fi cati on of pati ents 
based on the ADCmin percentage change in the enhancing lesions was unchanged. 
Kaplan-Meier curves of all pati ents together, both bevacizumab-treated groups, and 
the bevacizumab-treated groups separately using 27.5% decrease in ADCmin as a cut-
off  value are shown in Figure 4.
Figure 4 (A-D): Kaplan-Meier with 27.5% decrease of minimum apparent diff usion coeffi  cient (ADC-
min) as a cut-off  value in enhancing lesions (data from table 1), for all treatment groups together (A), 
for both bevacizumab-treated (bevacizumab monotherapy and bevacizumab plus lomusti ne com-
bined treatment) groups (B), for the bevacizumab plus lomusti ne group (C), and the bevacizumab 
monotherapy group (D).
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In non-enhancing lesions (n=99) (Supplementary Files: Table S2) there were no 
significant differences in OS after stratification of patients based on any of the ADCmin 
percentage change values.
discussion
In the context of the phase II BELOB-trial, we found that patients treated with beva-
cizumab and lomustine for recurrent glioblastoma had a significantly better OS, i.e. 
an indication of response, when there was a decrease of ADCmin in enhancing lesions 
after the first course of treatment than in those who didn’t show such a decrease. 
The optimum cut-off value for establishing response was 27.5% decrease in ADCmin. In 
patients treated with bevacizumab or lomustine monotherapy, or in non-enhancing 
lesions, an association between ADC changes and OS was not seen.
The significant difference in OS based on ADCmin was seen when patients from all 
treatment arms were combined as well as when all bevacizumab-treated patients 
were considered. These findings seemed to be driven by the combined treatment 
arm, as no significant effects were found in the monotherapy groups. Considering 
the BELOB-trial survival data, published previously15, patients treated with bevaci-
zumab plus lomustine showed a better OS then those treated with bevacizumab or 
lomustine alone. This result was however not reproduced in the subsequent phase 
III trial EORTC 2610119, possibly indicating differences between patient samples. We 
must therefore consider the possibility that our results are specific to the BELOB-trial 
population. However, the observed changes could also indicate true tumor response 
in a subset receiving combination treatment. Our results will need to be externally 
validated in order to generalize these. It should be noted that while exploratory 
analyses were performed in the same population as the test population, they were 
performed within the entire patient group without optimization for a specific treat-
ment arm nor was a specific threshold value established at this stage.
Because of tumor heterogeneity, changes in diffusion may differ between tumor 
regions20. Measures such as ADCmean and ADCmedian are therefore less insightful when 
considering lesions as a whole. Aside from ADCmin, skewness also showed promise, 
but in our analysis there were so many outliers in the ADCskew data that this param-
eter was considered unreliable.
A comparison between our study and previous studies is problematic, because of 
differences in patient populations (with varying number of recurrences or inclusion 
of grade III glioma), post-processing methods, treatment (bevacizumab monother-
apy and/or combined therapy groups), and measured time-points (pretreatment-
only; different follow-up). In a recent publication, Ellingson et al. conclude that pre-
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treatment diffusion histogram analysis can be predictive in recurrent GBM treated 
with angiogenesis inhibitor monotherapy21. Here, we focused on determining the 
response after treatment, which is known to be problematic in the context of anti-
angiogenic agents due to issues with pseudo-response. We specifically looked at the 
first moment of follow-up after start of treatment, assessing change in ADC from 
baseline to first follow-up, considering an early response assessment most relevant 
for treatment decisions. There are a few other studies assessing changes from base-
line to first follow-up. These measured volumes of foci with low ADC values within 
T2w/FLAIR abnormalities22-24, sometimes by means of a graded functional diffusion 
map (fDM)25. In these studies, low ADCmin at baseline and larger volumes of areas 
with low ADC values predicted a worse outcome.
Low ADC is hypothesized to reflect regions of high cellularity within the tumor25, 
which is consistent with worse outcome as established in previous studies22-24. Our 
seemingly contradictory results can be explained in light of the changes occurring 
after bevacizumab-treatment specifically. Anti-angiogenic treatment normalizes 
tumor vasculature leading to a decrease in enhancement, perfusion, and ADC7-9. 
Diffusion restriction could be the result of hypoxia, but could also be due to a reduc-
tion in blood volume. The decrease in ADC in those treated with both bevacizumab 
and chemotherapy may thus reflect a strong anti-angiogenic treatment induced 
anti-tumoral effect, resulting in better OS as an indication of treatment response. In 
patients not treated with bevacizumab, diffusion restriction likely corresponds with 
hypercellularity26, thus showing a negative impact on survival.
ADC changes in non-enhancing lesions were not predictive of OS. The T2w/FLAIR 
abnormalities in recurrent glioblastoma are generally a combination of non-enhanc-
ing tumor, edema, and treatment effects. Given the heterogeneity of the T2w/FLAIR 
abnormalities it is possible that differential effects were obscured.
Aside from the need to validate our findings in a different cohort, other limitations 
are the retrospective nature of the study, and the fact that these patients were all 
derived from a phase II trial.
In conclusion, we found that decreasing ADCmin in enhancing tumor from baseline 
to first follow-up in patients with recurrent glioblastoma treated with bevacizumab 
and lomustine predicted OS using a cut-off percentage change between 5 and 27.5% 
with a significantly better OS found in those with decreasing ADCmin. These results 
indicate that the assessment of ADC may have a role in predicting response after the 
first course of combined bevacizumab and lomustine treatment, but given the fact 
that findings are derived from data acquired in the context of a phase II trial, external 
validation in a wider cohort is required before these can be generalized to all patients 
treated with bevacizumab in combination with lomustine.
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In this thesis I investigated the value of several specific Magnetic Resonance Imaging 
(MRI) techniques in patients with recurrent glioblastoma treated with bevacizumab. 
In these patients, a phenomenon known as pseudo-response complicates treatment 
response assessment. I investigated a variety of methods for measuring treatment 
response in this patient group. Additionally, I investigated growth patterns in newly 





The appearance of new lesions in recurrent glioblastoma patients on T1-weighted 
post-contrast images or T2-weighted/FLuid Attenuated Inversion Recovery (FLAIR) 
images (i.e. enhancing or non-enhancing lesions) early after the start of treatment 
clearly is associated with poor overall survival (OS) with a mean OS of just 3.2 months 
for those with a new lesion compared to 11.2 months in those without a new lesion 
at 6 weeks follow-up. We can therefore conclude that the appearance of a new lesion 
is a strong predictor for OS. This effect is independent of treatment.
We compared the 2D Response Assessment in Neuro-Oncology (RANO) criteria 
with various volumetric methods: contrast-enhancing volume only (measured on 
either T1w post-contrast images or subtraction images) and contrast-enhancing 
volume plus non-enhancing volume (the latter measured on FLAIR images). The 
RANO criteria are the current method of choice for assessing treatment response 
in glioblastoma. According to the RANO criteria, progressive disease (PD) is defined 
as any of the following: ≥25% increase in the sum of perpendicular diameters of 
enhancing lesions or a significant increase in T2w/FLAIR non-enhancing lesions 
compared to baseline or best response scan after start of treatment, the appearance 
of new lesions, clear progression of non-measurable lesions, or clinical deterioration. 
Steroid dosage is also taken into account1. While the enhancing lesions are measured 
in 2D, the T2w/FLAIR non-enhancing lesions are not quantified. By measuring not 
only contrast-enhancing volume, but also non-enhancing volumes we hypothesized 
that survival prediction based on change in tumor size would improve.
Especially in patients treated with bevacizumab we hoped to find an improvement 
in survival prediction using volumetric measurements of non-enhancing lesions. 
Bevacizumab directly influences tumor vasculature (i.e. abnormal vasculature) by 
decreasing the permeability of the vessel wall, which may lead to a decrease in 
contrast-enhancement on T1-weighted post-contrast images. Since tumor activity 
has not decreased but is only masked, this effect is known as pseudo-response. Beva-
cizumab also alleviates edema and by doing so, decreases non-enhancing abnormali-
ties on T2w/FLAIR images. At progression, an increase in non-enhancing tumor has 
been described (gliomatosis cerebri), but whether this pattern of progression occurs 
more often in patients treated with bevacizumab has been questioned2-5.
We assessed both lomustine-only treated and bevacizumab-treated (with and 
without lomustine) patients and found that determining PD with volumetric meth-
ods did not significantly improve survival prediction at 6 and 12 weeks follow-up in 
any of the treatment groups and nor did subtraction techniques improve survival 
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prediction. Since volumetric assessment is more time-consuming, these findings 
support the use of 2D evaluation.
However, the threshold set for volumetric PD was ≥40% for enhancing tumor 
volume6-8 and ≥25% for non-enhancing volume9. To see whether different thresholds 
would lead to different results, we tested lower thresholds at both 6 and 12 weeks 
follow-up. We found that lowering the thresholds improved prediction and that this 
result persisted after removing patients with high percentages of increase in tumor 
size from the analysis. Despite the better survival prediction found with these lower 
thresholds, the number of additional patients categorized as progressors was quite low. 
This was especially the case in the bevacizumab-treated group in which only a small 
number of patients had increasing enhancing and/or non-enhancing tumor volume.
Diffusion Weighted Imaging
We also explored whether Apparent Diffusion Coefficient (ADC) histogram analysis 
would allow better outcome assessment. Some promising results for treatment 
response assessment were observed in patients treated with both bevacizumab and 
lomustine. In this group, a decrease in histogram derived minimum ADC values (AD-
Cmin) from the enhancing tumor volume from baseline to first follow-up significantly 
improved survival. Those with a decrease in ADCmin of >27.5% had a mean OS of 15.2 
months versus 6.8 months in those without this decrease. This effect was however 
not found in the bevacizumab-only and lomustine-only treatment arms, nor were 
significant results found when analyzing histograms from non-enhancing volumes.
Diffusion Tensor Imaging
A different diffusion technique is diffusion tensor imaging (DTI), which can be used to 
determine directionality of diffusion of water molecules. Where in DWI only the pres-
ence of diffusion restriction is measured (by measuring diffusion in 3 directions), many 
different directions of diffusion are measured with DTI. Subsequently, the general direc-
tion of diffusion within a voxel can be calculated. Directionality in the brain is strongest 
in white matter where diffusion occurs along white matter tracts (high anisotropic 
values) and lowest in the ventricles (high isotropic values). Disturbances in white matter 
architecture by a tumor are made apparent using DTI. A tumor can grow by infiltrating 
white matter tracts by pushing into them or growing alongside the fiber bundles.
DTI derived isotropic (p) and anisotropic (q) maps have previously been used 
by Price et al.10 to discern different molecular subtypes of glioblastoma (i.e. IDH-
mutated versus IDH wild-type) based on different patterns of growth into/along 
white matter tracts. The authors reconfirmed that Isocitrate dehydrogenase (IDH) 
mutated glioblastomas grow less invasively than IDH wild-type tumors and that this 
is associated with patient prognosis. We used the same technique in pretreated non-
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enhancing (presumed low-grade) gliomas to discern IDH-mutated and IDH wild-type 
tumors as well. We also looked at 1p19q codeleted versus non-codeleted tumors 
(i.e. molecular oligodendrogliomas versus astrocytomas) to see if there were differ-
ences in growth patterns between these molecular subtypes. Only 4 patients with an 
IDH-WT tumor were available for this analysis, but these all showed different growth 
patterns. These same 4 growth patterns were also found in the IDH-mutated group. 
1p19q codeleted and non-codeleted tumors were more evenly distributed, but no 
significant differences in growth patterns were found here either.
methodoloGical considerations
All four chapters on the BELOB-trial have their focus on finding a better method for 
treatment response assessment in bevacizumab-treated recurrent glioblastoma. 
Effectiveness of treatment can be determined by correlating this with the golden 
endpoint for oncology trials: overall survival (OS). To predict OS, a cox regression 
analysis can be performed in which hazard ratios (HRs) are calculated for those with 
and without progressive disease (PD) as determined per method. The evaluation 
method leading to the highest HR at a given time-point is the best method for pre-
dicting OS and most likely to reflect benefit in a phase III trial with OS as the primary 
endpoint. When interpreting these results, it is important to consider the number 
of patients that are categorized as progressors with a particular method and the 
overlap in confidence intervals between methods. This places results in a broader 
perspective (shown in chapter 3.2).
Different methods, such as DWI and perfusion imaging, can potentially provide other 
markers for treatment response in bevacizumab-treated patients. Regarding the results 
we found, it is important to note that our research took place within the context of a 
clinical trial and thus results are not directly generalizable to all patients with recurrent 
glioblastoma treated with other agents. This means that aside from validation in a dif-
ferent and larger cohort of patients, positive findings in our analysis would need to be 
confirmed in independent datasets and preferably in ‘real life’ clinical setting as well.
We also assessed non-enhancing glioma growth patterns with DTI. We reproduced a 
p/q mapping technique that was previously found successful for discerning molecu-
lar subtypes of glioblastoma10,11. The methodology included the drawing of volumes 
of interest (VOIs) on both the p and q maps and subsequently overlaying the two 
in order to detect mismatch. Mismatch was determined if the p-VOI exceeded the 
q-VOI by >0.5cm, although in the 2017 publication by Price, a cut-off of 1.0cm was 
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used. Three diff erent patt erns of mismatch were described: a minimally invasive pat-
tern, a localized patt ern, and a diff use patt ern.
Reproducing the exact methodology proved diffi  cult: drawing a volume of interest 
(VOI) on the q-map was unreliable as many variati ons were possible within a single 
pati ent (Figure 1). Instead we overlaid the p-VOI on the q-map and scored where 
the p-VOI overlapped high intensity areas on the q-map (i.e. white matt er tracts), 
basically measuring the invasiveness of the tumor into white matt er tracts. However, 
the three categories described by Price et al. did not adequately defi ne the patt erns 
we encountered and we instead used 5 diff erent categories. One of the reasons for 
doing so, is that we found that some tumors would expand into white matt er tracts, 
while others would follow the tracts in a more infi ltrati ve fashion.
Because of the many possible variati ons in delineati on of the q-VOI, as well as the 
diff erent patt erns of infi ltrati ve growth encountered, we were unable to reproduce 
the exact method used by Price. Possibly, our diff erent pati ent characteristi cs, i.e. 
glioblastoma versus non-enhancing gliomas, are to blame. However, when evaluat-
ing the specifi c problems we encountered, we fi nd that the technique itself is not 
reliable and/or robust enough for applicati on. The lack of positi ve results and in 
parti cular the four diff erent patt erns found in the IDH-WT pati ents was unexpected 
given the highly positi ve results found by Price in glioblastomas. The diffi  culti es we 
encountered reproducing the method were refl ected in the low interrater agree-
ment of 62.7%. In fact, the troubles we encountered using this technique could have 
obscured possible actual diff erences in growth patt erns between the molecular 
subtypes of gliomas in our cohort.
Clinical Implications and future directions
The associati on between the appearance of new lesions and survival has direct 
clinical implicati ons. The associati on found was independent of treatment. We 
found that the negati ve impact of a new lesion on overall survival is stronger than 
that of increasing tumor volume. We scored and measured both enhancing and 
Figure 1. DTI-derived isotropic map (A), anisotropic map (B), and three possible volume of interest 
(VOI) drawings (C, D, E).
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non-enhancing new lesions of any size that persisted or increased in volume at the 
subsequent follow-up scan (i.e. 6 weeks later). While the appearance of a new lesion 
is already included in the definition of ‘progressive disease’ as described in the RANO 
criteria, we find that more emphasis on the appearance of new lesions is needed.
(Semi)-automated volumetric tumor measures have lower intra- and interrater 
variability than manual measures, including 2D measures7,12. Heterogeneous tumors 
with lots of necrosis, as is the case in glioblastoma, are more difficult to measure in 
an axial plane and the axial plane itself is influenced by head position and slice align-
ment. These are strong arguments for using volumetric instead of 2D measurements. 
However, volumetric methods are time-consuming for various reasons: I) it takes time 
to send the MRI-sequence to a dedicated work-station with software for volumetric 
segmentation and then it takes time to send the information back to the main system, 
and II) an segmentation by (semi)-automated techniques is based on algorithms that 
often include non-tumorous areas into the volume of interest (VOI). Examples are the 
inclusion of blood vessels and dura into an enhancing VOI and the inclusion of the 
cortical ribbon into a non-enhancing VOI. This means that manual work is needed to 
check the VOIs and to adjust them where necessary, which is time-consuming.
Only if (semi)-automated techniques became more readily available and faster 
than is currently the case, would we advise volumetric methods over 2D measures. 
At present there is no reason to switch to volumetric methods.
When it comes to the thresholds currently in use for determining PD, we see no 
reason to lower them at this time as the number of patients additionally categorized 
as progressors is quite low in our study cohort.
In recurrent glioblastoma patients treated with bevacizumab, only a few have 
increasing enhancing (and non-enhancing) tumor volumes at first follow-up, despite 
the absence of true anti-tumor activity of this agent. More advanced methods for 
measuring treatment outcome should therefore be considered, unless bevacizumab 
is only considered as a steroid-like drug. For instance, change in ADCmin in enhancing 
tumor in recurrent glioblastoma treated with both bevacizumab and lomustine is a 
very promising predictor for overall survival. There was a clear difference in survival 
between those with a decrease in ADCmin and those without. As mentioned before, 
these results will need to be validated in a different and larger cohort.
Since we were unable to discern different molecular subtypes of non-enhancing 
gliomas using p/q-mapping based on different growth patterns and because of the 
difficulties we encountered when using this technique, we currently do not recom-
mend using this technique in non-enhancing gliomas.
Other techniques that could be used to look at white matter changes due to 
tumor infiltration are tractography, FA-skeletons, and fiber density mapping. In 
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tractography, the orientation of diffusion is determined for every voxel individually, 
after which the voxels are linked together to visualize diffusion occurring along white 
matter tracts13,14. White matter tracts can also be made visible by setting a threshold 
above which diffusion is considered anisotropic (generally FA is used) for the whole 
brain. A ‘skeleton’ of white matter tracts appears, commonly referred to as a FA-
skeleton15. In both tractography and FA-skeleton techniques, a threshold is needed 
to prevents tracts from being ‘drawn’ outside the white matter. The chosen threshold 
affects the results. Fiber density mapping is a postprocessing method that includes 
the reconstruction of all fiber paths in the brain and calculations of fiber density 
values per voxel while also using measures from adjacent voxels. It is an additional 
measure to FA-skeleton maps and tractography and can help quantify the extent of 
destruction of white matter16. While the extent of destruction and the type of white 
matter damage can be determined using these techniques, it is unclear if they can 
be used to determine growth patterns and if results can provide information on the 
molecular subtype of the tumor. Instead of looking at affected white matter, one 
could also look at a variety of parameters to see which correlate with molecular 
tumor subtypes. This method is known as radiogenomics and it has the ability to look 
at very large datasets and numerous parameters from different MRI sequences (and 
other imaging methods) from which a predictive model can be calculated.
conclusions
There is currently no reason to change the 2D treatment response measures to volu-
metric measures in recurrent glioblastoma, nor is there a reason to adjust thresholds 
for measuring progressive disease. More attention to early appearing new lesions is 
justified to optimize survival prediction and deciding on the continuation of treat-
ment within the currently used 2D RANO criteria.
Measuring change in minimum ADC measured in enhancing tumor from baseline 
to first follow-up is a promising tool for determining treatment response in recurrent 
glioblastoma treated with both bevacizumab and lomustine.
Possible differences in growth-patterns between different molecular subtypes of 
non-enhancing glioma cannot be discerned using DTI-derived isotropic and anisotro-
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Gliomas encompass a spectrum of primary brain tumors with different prognoses 
based on the exact tumor type. Originally, patient prognosis was determined by 
the histological tumor grade. Grade I and II gliomas are considered low-grade and 
bear a better prognosis than high-grade (III and IV) gliomas. However, categorizing 
gliomas based on molecular characteristics instead of histology has been shown to 
significantly improve survival prediction. The most important molecular markers in 
glioma are of the chromosome armes 1p and 19q and the isocitrate dehydrogenase 
gene 1 and 2 (IDH) status.
IDH mutated (IDHmt) gliomas bear in general a better prognosis than IDH wild-type 
(IDHwt) gliomas and if a codeletion of 1p19q is present (i.e. oligodendroglioma) the 
prognosis is better as well. An association between these molecular characteristics 
and specific MRI measures has previously been described. In Chapter 2 we inves-
tigated whether IDHmt could be predicted using imaging in ‘presumed low-grade’ 
gliomas, which show no enhancement on a T1-weighted image after the administra-
tion of intravenous contrast. Using a technique called Diffusion Tensor Imaging (DTI) 
we aimed to determine the molecular status of the tumor. Where invasive growth in 
IDHwt compared to IDHmt grade IV gliomas (i.e. glioblastoma) had previously been 
described, we found no such results in the presumed low-grade gliomas and were 
therefore unable to determine molecular status based on imaging alone.
Glioblastoma are grade IV gliomas that have a 5-year survival rate of approximately 
10%. Initial treatment includes surgery, chemotherapy and radiotherapy. Further 
treatment can consist of re-surgery and different types of chemotherapy. Recently, 
the US Food and Drug Administration (FDA) approved bevacizumab (Avastin) for use 
in glioblastoma. Bevacizumab is an angiogenesis inhibitor and inhibits Vascular En-
dothelial Growth Factor (VEGF). VEGF is produced in high quantities by glioblastoma 
and induces angiogenesis resulting in an abnormal tumor vasculature with ‘leaky’ 
blood vessels. The abnormal blood vessels will partially normalize when VEGF signal-
ing is inhibited resulting in a decrease of the abnormal leakiness.
The results of bevacizumab-treatment can be demonstrated on MRI. After ad-
ministration of intravenous contrast, the tumor will ‘enhance’ due to the contrast-
agent leaking out of the abnormal blood vessels. Since bevacizumab normalizes 
the vasculature, the enhancement of the tumor decreases and edema diminishes. 
Despite these changes on MRI suggestive of a decrease in tumor activity, the tumor 
activity may not have changed at all and these bevacizumab-induced changes on 
MRI imaging have been called ‘pseudo-response’ to reflect that. The main focus of 
the research presented in this thesis is on finding new and better ways to determine 
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treatment response in patients with recurrent glioblastoma treated with or without 
bevacizumab.
In chapter 3.2 conventional 2D tumor measurements are compared with semi-
automated volumetric methods. While measurements in tumor volume very 
accurately reflect changes, they didn’t improve survival prediction. However, since 
we used volumetric thresholds set for determining progressive disease (PD) that are 
a direct extension of 2D thresholds, we considered that using different thresholds 
might improve survival prediction. In order to find the optimal threshold we looked 
at both enhancing tumor portion and non-enhancing abnormalities (including tumor, 
radiation effects and edema). The results, shown in chapter 3.3, include that early 
increase in enhancing (and non-enhancing) volumes is rare in patients treated with 
bevacizumab, but that lowering thresholds did improve survival prediction. In con-
trast, the occurrence of a new lesion early after the start of treatment was strongly 
associated with poor overall survival.
In addition to measuring tumor volumes, we also used a more advanced MRI 
method to determine treatment response in chapter 3.4. With Diffusion Weighted 
Imaging (DWI), the degree of movement of water molecules within a voxel can be 
measured. Enhancing portions of glioblastoma in patients treated with both be-
vacizumab and lomustine showed a clear decrease in minimal Apparent Diffusion 
Coefficient (ADCmin) in a subset of patients. These patients had a significantly better 
overall survival compared to patients without a decrease in ADCmin, making DWI a 
possible alternative for determining treatment response in this treatment group.
Other challenges in treatment response assessment come from radiotherapy treat-
ment and include a phenomenon known as pseudo-progression. Gliomas (especially 
high-grade) and other intra-cranial tumors such as meningiomas and metastases 
are treated with radiotherapy. In chapter 3.1, different MRI and nuclear imaging 





De meest voorkomende primaire hersentumoren zijn gliomen. De term glioom om-
vat een heel spectrum aan subtypen. Vroeger werd de prognose bij deze patiënten 
bepaald door de histologische tumorgradering waarbij laaggradige gliomen (graad I 
en II) een betere prognose hebben dan hooggradige gliomen (graad III en IV). Er is 
echter gebleken dat het indelen van gliomen op basis van moleculaire eigenschappen 
tot een veel betere voorspelling van de overleving leidt. De belangrijkste moleculaire 
eigenschappen bepalend voor de prognose zijn verlies van de chromosoomarmen 
1p en 19q, en de status van het gen dat codeerd voor isocitraat dehydrogenase 1 of 
2 (IDH).
IDH gemuteerde (IDHmt) gliomen hebben een betere prognose dan IDH wild-type 
(IDHwt) gliomen. Een IDHmt tumor met codeletie van de chromosoomarmen 1p en 
19q (diagnostisch voor een oligodendroglioom) heeft een betere prognose. In eerder 
onderzoek is er een associatie gevonden tussen deze moleculaire tumoreigenschap-
pen en specifieke MRI-kenmerken. In Hoofdstuk 2 hebben we onderzocht of we IDH 
mutaties konden voorspellen met MRI bij ‘waarschijnlijk laaggradige gliomen’, welke 
zich kenmerken door een gebrek aan aankleuring na toediening van intraveneus 
contrast. Met een techniek genaamd Diffusion Tensor Imaging (DTI) hebben we 
geprobeerd de moleculaire status van de tumor te bepalen. Gezien de associatie 
gevonden in eerder onderzoek in een populatie van patiënten met hooggradige 
gliomen (graad IV), hoopten we vergelijkbare uitkomsten te genereren. Wij vonden 
echter geen associatie en hebben daarom moeten concluderen dat deze methode 
niet geschikt is als niet-invasieve methode voor het bepalen van moleculaire status.
Glioblastomen zijn graad IV gliomen met een 5-jaars overleving van ca. 10%. De 
behandeling bestaat uit chirurgische resectie, chemotherapie en radiotherapie. De 
tumor recidiveert altijd en wordt vervolgens opnieuw behandeld. Opties zijn o.a. 
re-resectie en chemotherapie. Sinds kort heeft de Amerikaanse Food and Drug 
Administration (FDA) gebruik van het middel bevacizumab (Avastin®) goedgekeurd 
voor gebruik bij patiënten met een eerste recidief glioblastoom. Bevacizumab remt 
Vascular Endothelial Growth Factor (VEGF) wat in grote hoeveelheden geproduceerd 
wordt door het glioblastoom. VEGF induceert nieuwe, maar abnormale, lekkende 
bloedvaten in de tumor waardoor de tumor op de MRI scan ‘aankleurt’ na toedien-
ing van intraveneus contrast. Bevacizumab normaliseert de bloedvaten waardoor 
de tumor niet of minder aankleurt en ook het oedeem (zwelling) rondom de tumor 
neemt af. Echter, ondanks deze verbeteringen van de MR afwijkingen is de tumor 
vaak onveranderd aanwezig en deze door bevacizumab geïnduceerde veranderingen 
zijn als ‘pseudo-response’ betiteld. Het grootste deel van mijn onderzoek is gericht 
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op het vinden van een goede manier om behandelrespons te meten bij patiënten 
met een eerste recidief glioblastoom behandeld met bevacizumab en/of lomustine.
In Hoofdstuk 3.2 hebben we 2D metingen vergeleken met volumemetingen. 
Ondanks dat volumemetingen een betere weerspiegeling zijn van de tumoromvang, 
verbeterde de overlevingsvoorspelling niet wanneer er volumes in plaats van 2D 
metingen werden uitgevoerd. We hebben echter hiervoor afkapwaarden gebruikt 
die zijn afgeleid van de 2D afkapwaarden voor het bepalen van tumorprogressie, mo-
gelijk zijn andere afkapwaarden beter in staat de overleving te voorspellen. Daarom 
hebben we verschillende afkapwaarden getest voor zowel volumes aankleurende 
tumor en niet-aankleurende afwijkingen (bestaande uit tumor, bestralingseffecten 
en oedeem). De resultaten worden uiteengezet in Hoofdstuk 3.3. Een vroege toe-
name in volume bij patiënten behandeld met bevacizumab bleek zeldzaam, maar het 
verlagen van de afkapwaarden verbeterde wel de overlevingsvoorspelling. Daarnaast 
vonden we dat het ontstaan van nieuwe afwijkingen na het starten van behandeling 
geassocieerd was met een significant slechtere overleving.
Ook hebben we een meer geavanceerde MRI methode gebruikt om behandelre-
spons te meten. In Hoofdstuk 3.4 gebruiken we Diffusion Weighted Imaging (DWI) 
om de bewegingsvrijheid van watermoleculen te meten binnen een voxel. Bij een 
subset van de patiënten die zijn behandeld met de combinatie bevacizumab and lo-
mustine bleek binnen het aankleurende deel van het glioblastoom er een duidelijke 
afname in minimale Apparent Diffusion Coëfficiënt (ADCmin) te zien. Deze patiënten 
bleken een significant betere overleving te hebben en het meten van ADCmin zou 
derhalve als alternatief kunnen dienen bij het meten van behandelrespons.
Andere uitdagingen bij het meten van behandelrespons worden behandeld in 
Hoofdstuk 3.1. Een belangrijke behandeling bij patiënten met hooggradige gliomen, 
maar ook meningiomen en metastasen, is radiotherapie. Naast tumorrespons op de 
radiotherapie kan er ook een fenomeen optreden bekend als pseudoprogressie. In dit 
hoofdstuk bespreken we verschillende MRI en nucleaire beeldvormende technieken 
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maar dan via Skype. Ik kan me geen betere supervisor bedenken.
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onbelangrijk, het goedkeuren) van mijn proefschrift. En de grotere commissie, Jacoline 
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het werk hebben we veel mooie dingen samen meegemaakt zoals congresbezoeken, 
de Efteling, baby-bezoeken en natuurlijk op bezoek bij Rozanna in Edinburgh!
Rebecca, ik heb niet voor niets gevraagd of je mijn paranimf wilde zijn. De afgelopen 
jaren was jij er altijd zowel op werk als bij onze vele uitjes. Je bent een hele goede 
vriendin van me geowrden en ik ben altijd blij als we samen op pad zijn.
Rozanna, jij was een van mijn muziek-buddies op de kamer. Het was altijd gezellig 
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jullie stonden altijd klaar om te helpen.
Mijn co-auteurs, met in het bijzonder Sebastian en Maarten, wil ik bedanken voor de 
fijne samenwerking. Ronnie, jou wil ik graag bedanken voor alle nuttige commenta-
ren die je mij hebt toegestuurd.
Juan Antonio and Alexandra, I would very much like to thank you both for helping out 
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Olga en Roos, mijn beste vriendinnen en metalbuddies, heel erg bedankt voor alle 
leuke momenten de afgelopen jaren. Ik kan altijd op jullie rekenen en we hebben 
altijd zoveel lol samen. En eigenlijk vallen Alex, Tai-Pau en Oscar als mede-Wacken-
gangers natuurlijk ook onder metalbuddies tegenwoordig!
Lieve Anouk, wij gaan al jaren dezelfde richting op en dat maakt dat we altijd samen 
in onbegrijpelijk radiologische taal kunnen praten terwijl iedereen om ons heen zich 
afvraagt of het wel goed met ons gaat. Je bent een van mijn beste vriendinnen en wie 
weet worden we ooit nog eens directe collega’s.
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